[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 738
1. Marnitz S, Köhler C, Roth C, Füller J, Bischoff A, Wendt T, Schneider A, Budach V: Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. Strahlenther Onkol; 2007 Sep;183(9):473-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging.
  • PATIENTS AND METHODS: 101 patients with cervical cancer FIGO IB1-IVB underwent chemoradiation after transperitoneal laparoscopic staging.
  • CONCLUSION: In patients with cervical cancer, laparoscopic staging led to an upstaging of 83% of cases with significant impact on therapeutic strategies.
  • Pretherapeutic laparoscopic staging should be the basis of the primary chemoradiation in patients with cervical cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Laparoscopy. Lymphatic Metastasis / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymph Node Excision. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy Dosage. Rectum / pathology. Survival Rate. Urinary Bladder / pathology


2. Yamamoto T, Yoshioka N, Katoh Y, Iguchi M, Katoh M, Yamazaki M: [A case of sigmoid colon cancer that spread to the urinary bladder via the ureter]. Hinyokika Kiyo; 2005 Oct;51(10):673-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of sigmoid colon cancer that spread to the urinary bladder via the ureter].
  • A year ago, he underwent sidmoidectomy to cure sigmoid colon cancer diagnosed as stage IV.
  • Then, a ureteral tumor was suspected and urinary cytology was class V.
  • Because the histopathological manifestation by transurethral resection of bladder tumor and that by the sidmoidectomy were consistent, it was considered that sigmoid colon cancer spread to the urinary bladder via the left ureter.
  • There have been only 4 reported cases of adenocarcinoma that multiplied in the ureter, and this is the fifth case report.
  • [MeSH-major] Adenocarcinoma / pathology. Lymph Nodes / pathology. Sigmoid Neoplasms / pathology. Ureteral Neoplasms / pathology. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Aged. Colon, Sigmoid / surgery. Diagnosis, Differential. Humans. Hydronephrosis / complications. Lymphatic Metastasis. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285621.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Mori H, Ohno Y, Ito F, Funaguchi N, Yanase K, Endo J, Nakano M, Bai La BL, Minatoguchi S: Massive hematuria from the bilateral upper urinary tract in a patient treated for advanced lung cancer with gefitinib. Jpn J Clin Oncol; 2010 Mar;40(3):263-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive hematuria from the bilateral upper urinary tract in a patient treated for advanced lung cancer with gefitinib.
  • We report a case of gefitinib-induced bilateral upper urinary tract bleeding in an 82-year-old woman administered the drug daily for advanced non-small cell adenocarcinoma of the lung (T4N3M0).
  • Cystoscopy revealed bleeding from the bilateral ureteric orifices without hemorrhagic inflammation of the bladder.
  • Instead, the reproducibility of the hematuria from the upper urinary system strongly suggests an unexpected gefitinib-related adverse effect.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / adverse effects. Hematuria / chemically induced. Lung Neoplasms / drug therapy. Quinazolines / adverse effects. Urinary Tract / drug effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19897850.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


Advertisement
4. Di Carlo A, Terracciano D, Mariano A, Macchia V: Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors. Oncol Rep; 2006 May;15(5):1321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
  • By gelatin zymography, we verified MMP activity in the urine of patients with bladder cancer.
  • Of these patients, 10 had well-, 8 had moderately and 7 had poorly differentiated bladder cancer.
  • Moreover, MMP-9 content is enhanced in the urine from patients with high-grade and advanced-stage bladder tumors.
  • Finally, we determined the urinary levels of urinary bladder cancer (UBC), tissue polypeptide-specific antigen (TPS) and protein 22 of nuclear matrix (NMP22).
  • The levels of TPS and NMP-22 were higher in G3 bladder cancer than in G1 and G2 neoplasias.
  • The urinary values of these two biomarkers correlated with the increase in MMP-9 lytic activity in high-grade and advanced-stage bladder cancer.
  • [MeSH-major] Adenocarcinoma / urine. Matrix Metalloproteinase 2 / urine. Matrix Metalloproteinase 9 / urine. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / urine. Case-Control Studies. Cathepsin B / urine. Female. Humans. Male. Middle Aged. Neoplasm Staging. Nuclear Proteins / urine. Peptides / urine. Urinary Bladder / metabolism. Urokinase-Type Plasminogen Activator / urine

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596205.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Peptides; 0 / nuclear matrix protein 22; 0 / tissue polypeptide specific antigen; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.22.1 / Cathepsin B; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


5. Adhikari RC, Tuladhar A, Shrestha S, Sharma SK: Deep-seated thoracic and abdominal lesions: usefulness of ultrasound guided fine needle aspiration cytology, a 3 year experience. Nepal Med Coll J; 2010 Mar;12(1):20-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These included liver (125 cases), lung (81 cases), abdominal and mediastinal lymph nodes (29 cases), ovary (14 cases), omentum (12 cases), pancreas (10 cases), kidney (10 cases), mediastinum (8 cases), gall bladder (8 cases) etc.
  • The aim of this study was to evaluate the overall utility of ultrasonographic guided FNAC in the diagnosis of abdominal and thoracic lesions.
  • In 264 cases (82.5%), FNAC was diagnostic with commonest diagnosis being malignant neoplasm (70.0%).
  • In liver, Metastatic adenocarcinoma is the commonest tumor, while in lung; the commonest lesion is non-small cell carcinoma.
  • [MeSH-major] Neoplasms / diagnosis. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677604.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


6. Cerqueira NM, Pereira S, Fernandes PA, Ramos MJ: Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy. Curr Med Chem; 2005;12(11):1283-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Taking in account that DNA replication and repair are essential mechanisms for cell integrity and are dependent on the availability of deoxyribonucleotides, many researchers are giving special attention to this enzyme, since it is an attractive target to treat several diseases of our time specially cancer.
  • This investment has already given some benefits since some of these inhibitors show potent chemotherapeutic efficacy against a wide range of tumours such as non-small cell lung cancer, adenocarcinoma of pancreas, bladder cancer, leukaemia and some solid tumours.
  • In fact a few of them have already been approved for the clinical treatment of some kinds of cancer.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15974997.001).
  • [ISSN] 0929-8673
  • [Journal-full-title] Current medicinal chemistry
  • [ISO-abbreviation] Curr. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Ribonucleotides; EC 1.17.4.- / Ribonucleotide Reductases
  • [Number-of-references] 172
  •  go-up   go-down


7. Kondo T: Bile duct adenocarcinoma with minor micropapillary component: a case report. Cases J; 2009;2(1):51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bile duct adenocarcinoma with minor micropapillary component: a case report.
  • This histologic pattern has been described in various organs, including the breast, lung, urinary bladder, ovary, stomach, pancreas, and major salivary glands.
  • Here a case of bile duct adenocarcinoma with minor micropapillary component is described.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 2008 Aug;53(8):2287-9 [18224441.001]
  • [Cites] Pancreas. 2007 Aug;35(2):190-2 [17632330.001]
  • [Cites] Hum Pathol. 2006 Jul;37(7):809-15 [16784979.001]
  • [Cites] Mod Pathol. 2005 Nov;18(11):1504-11 [16007065.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):358-64 [11859208.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1224-32 [7977945.001]
  • [Cites] Adv Anat Pathol. 2004 Nov;11(6):297-303 [15505530.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):319-26 [15104294.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • (PMID = 19144165.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2639564
  •  go-up   go-down


8. Prieto MC, Matousek P, Towrie M, Parker AW, Wright M, Ritchie AW, Stone N: Use of picosecond Kerr-gated Raman spectroscopy to suppress signals from both surface and deep layers in bladder and prostate tissue. J Biomed Opt; 2005 Jul-Aug;10(4):44006
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of picosecond Kerr-gated Raman spectroscopy to suppress signals from both surface and deep layers in bladder and prostate tissue.
  • Prostate samples for this study were obtained by taking a chip at the transurethral resection of the prostate (TURP), and bladder samples from a biopsy taken at transurethral resection of bladder tumor (TURBT) and TURP.
  • Spectra obtained through the bladder and prostate gland tissue, at different time delays after the laser pulse, clearly show change in the spectra as depth profiling occurs, eventually showing signals from the uric acid cell and urea cell, respectively.
  • We show for the first time, using this novel technique, that we are able to obtain spectra from different depths through both the prostate gland and the bladder.
  • This has major implications in the future of Raman spectroscopy as a tool for diagnosis.
  • With the help of Raman spectroscopy and Kerr gating, it may be possible to pick up the spectral differences from a small focus of adenocarcinoma of the prostate gland in an otherwise benign gland, and also stage the bladder cancers by assessing the base of the tumor post resection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Prostatic Neoplasms / chemistry. Prostatic Neoplasms / diagnosis. Spectrum Analysis, Raman / methods. Urinary Bladder Neoplasms / chemistry. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Algorithms. Artifacts. Humans. Male. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178640.001).
  • [ISSN] 1083-3668
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


9. Taverna G, Corinti M, Colombo P, Grizzi F, Severo M, Piccinelli A, Giusti G, Benetti A, Zucali PA, Graziotti P: Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation. BMC Cancer; 2010;10:62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation.
  • BACKGROUND: Appendiceal adenocarcinoma is rare with a frequency of 0.08% of all surgically removed appendices.
  • Few cases of appendiceal carcinoma infiltrating the bladder wall for spatial contiguity have been documented.
  • CASE PRESENTATION: A case is reported of a 45-years old woman with mucinous cystadenocarcinoma of the appendix with bladder metastasis.
  • Although ultrasonography and voided urinary cytology were negative, abdomen computed tomography (CT) scan and cystoscopy and subsequent pathological examination revealed a mass exclusively located in the anterior wall of the bladder.
  • Histopathology of the transurethral bladder resection revealed a bladder adenocarcinoma [6 cm (at the maximum diameter) x 2,5 cm; approximate weight: 10 gr] with focal mucinous aspects penetrating the muscle and perivisceral fat.
  • The subsequent pathological examination revealed a mucinous cystadenocarcinoma of the appendix with metastatic cells colonising the anterior bladder wall and several colic lymph nodes.
  • CONCLUSIONS: The rarity of the appendiceal carcinoma invading the urinary bladder and its usual involvement of nearest organs and the posterior bladder wall, led us to describe this case which demonstrates the ability of the appendiceal cancer to metastasize different regions of urinary bladder.
  • [MeSH-major] Appendiceal Neoplasms / pathology. Cystadenocarcinoma, Mucinous / secondary. Urinary Bladder Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2001 Apr;8(4):196-8 [11260355.001]
  • [Cites] Hinyokika Kiyo. 2002 Jun;48(6):351-4 [12166235.001]
  • [Cites] J Urol. 1980 Apr;123(4):590-1 [6245280.001]
  • [Cites] Can J Surg. 1982 Sep;25(5):553-5 [7116255.001]
  • [Cites] J Urol. 1987 Sep;138(3):617-8 [3041057.001]
  • [Cites] J Dig Dis. 2008 Aug;9(3):175-7 [18956597.001]
  • [Cites] Br J Urol. 1996 Aug;78(2):305-6 [8813936.001]
  • [Cites] Urol Int. 1997;58(2):124-7 [9096277.001]
  • [Cites] World J Gastroenterol. 2005 Aug 14;11(30):4761-3 [16094726.001]
  • [Cites] Int Urol Nephrol. 2006;38(3-4):481-2 [17160444.001]
  • [Cites] J Urol. 1995 Apr;153(4):1220-1 [7869505.001]
  • (PMID = 20178637.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2836301
  •  go-up   go-down


10. Pinthus JH, Haddad R, Trachtenberg J, Holowaty E, Bowler J, Herzenberg AM, Jewett M, Fleshner NE: Population based survival data on urachal tumors. J Urol; 2006 Jun;175(6):2042-7; discussion 2047
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Urachal carcinoma accounts for less than 1% of all bladder cancers.
  • MATERIALS AND METHODS: We reviewed the data source of the Ontario Cancer Registry for patients diagnosed with urachal cancer during 1976 to 2001.
  • A cohort of 40 patients with urachal adenocarcinoma was found.
  • Disease specific mortality was not evident after 7 years from diagnosis.
  • CONCLUSIONS: Urachal adenocarcinoma occurs in all age groups.
  • [MeSH-major] Adenocarcinoma / mortality. Urachus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697798.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Wong-You-Cheong JJ, Woodward PJ, Manning MA, Sesterhenn IA: From the Archives of the AFIP: neoplasms of the urinary bladder: radiologic-pathologic correlation. Radiographics; 2006 Mar-Apr;26(2):553-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From the Archives of the AFIP: neoplasms of the urinary bladder: radiologic-pathologic correlation.
  • In the United States, primary bladder neoplasms account for 2%-6% of all tumors, with bladder cancer ranked as the fourth most common malignancy.
  • Ninety-five percent of bladder neoplasms arise from the epithelium; the most common subtype is urothelial carcinoma, which accounts for 90% of cases.
  • Adenocarcinoma (primary bladder, urachal, or metastatic) represents less than 2%.
  • Bladder cancer typically occurs in men aged 50-70 years and is related to smoking or occupational exposure to carcinogens.
  • Squamous cell carcinoma and adenocarcinoma occur in the setting of chronic bladder infection and irritation.
  • Mesenchymal tumors represent the remaining 5% of bladder tumors, with the most common types being rhabdomyosarcoma, typically seen in children, and leiomyosarcoma, a disease of adults.
  • Although imaging findings are not specific for these tumors, patterns of growth and tumor characteristics may allow differentiation.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / epidemiology. Magnetic Resonance Imaging. Tomography, X-Ray Computed. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549617.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 75
  •  go-up   go-down


12. Gawkowska-Suwinska M, Fijałkowski M, Białas B, Szlag M, Kellas-Ślęczka S, Nowicka E, Behrendt K, Plewicki G, Smolska-Ciszewska B, Giglok M, Zajusz A, Owczarek G: Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy. J Contemp Brachytherapy; 2009 Dec;1(4):211-215
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage brachytherapy for local recurrences of prostate cancer treated previously with radiotherapy.
  • PURPOSE: The aim of the study was to analyze early effects and toxicity of salvage high dose rate brachytherapy for local recurrences of adenocarcinoma of the prostate after external beam radiotherapy (EBRT).
  • MATERIAL AND METHODS: In MCS Memorial Institute of Oncology in Gliwice a research programme on salvage HDR brachytherapy for local recurrences of prostate cancer treated previously with EBRT has been ongoing since February 2008.
  • Maximal bladder and rectum doses were constrained to be ≤ 70% of the prescribed dose.
  • For bladder EORTC/RTOG score ranged from 0 to 2.
  • Other patients did not have any other significant late toxicity of the treatment.
  • CONCLUSIONS: Salvage brachytherapy for localized prostate cancer (3 × 10 Gy every 14 days) seems to be a safe and well tolerated procedure.
  • A significant decline in prostate-specific antigen (PSA) level is seen in patients with hormone-responsive cancer.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28050174.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; prostate cancer / radiotherapy / recurrences / salvage brachytherapy
  •  go-up   go-down


13. Bensalah K, Fleureau J, Rolland D, Rioux-Leclercq N, Senhadji L, Lavastre O, Guillé F, Patard JJ, de Crevoisier R: [Optical spectroscopy: a new approach to assess urological tumors]. Prog Urol; 2010 Jul;20(7):477-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La spectroscopie optique : une nouvelle approche pour l'étude des tumeurs urologiques.
  • Optical spectroscopy can differentiate benign (adenoma or inflammation) and malignant (adenocarcinoma) prostatic tissues.
  • It can also distinguish normal bladder tissue from inflammatory or cancerous cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20656268.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] France
  •  go-up   go-down


14. Suzuki T, Togo Y, Yasuda K, Yamamoto H, Kokura K, Nagareda T: [Prostatic duct adenocarcinoma with pagetoid spread on the glans penis: a case report]. Hinyokika Kiyo; 2006 Nov;52(11):887-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prostatic duct adenocarcinoma with pagetoid spread on the glans penis: a case report].
  • The patient underwent total cystoprostatectomy under the diagnosis of urothelial carcinoma of the urinary bladder four years earlier.
  • At the time, the prostatectomy specimen incidentally revealed a prostatic acinar adenocarcinoma at the bilateral peripheral zone.
  • A skin biopsy of the erythema revealed intraepithelial Paget's cells, and the patient underwent total penectomy under the diagnosis of extramammary Paget's disease.
  • Re-examination of the previous prostatectomy specimen revealed prostatic duct adenocarcinoma with prostatic acinar adenocarcinoma.
  • Therefore, the final diagnosis was prostatic duct adenocarcinoma with Pagetoid spread to the glans penis.
  • [MeSH-major] Adenocarcinoma / pathology. Paget Disease, Extramammary / pathology. Penile Neoplasms / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Aged. Carcinoma / pathology. Humans. Male. Neoplasms, Multiple Primary / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17176876.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


15. Gardner JM, Khurana H, Leach FS, Ayala AG, Zhai J, Ro JY: Adenocarcinoma in ectopic prostatic tissue at dome of bladder: a case report of a patient with urothelial carcinoma of the bladder and adenocarcinoma of the prostate. Arch Pathol Lab Med; 2010 Sep;134(9):1271-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in ectopic prostatic tissue at dome of bladder: a case report of a patient with urothelial carcinoma of the bladder and adenocarcinoma of the prostate.
  • We report a case of ectopic prostate tissue with an associated prostatic adenocarcinoma occurring in the dome of the urinary bladder.
  • A 62-year-old man presented with a 4-month history of persistent microscopic hematuria following a urinary tract infection.
  • Cystoscopic examination revealed a sessile lesion of the anterior bladder neck and multiple smaller papillary lesions throughout the bladder.
  • Following a transurethral resection of the bladder tumor with a diagnosis of muscle-invasive transitional cell carcinoma grade 3, a radical cystoprostatectomy was performed.
  • The diagnosis of transitional cell carcinoma was confirmed, but in addition, a different lesion was also incidentally found in the dome of the bladder.
  • This incidental lesion showed a prostatic adenocarcinoma arising from ectopic prostatic tissue within the bladder submucosa.
  • The prostate also showed prostatic adenocarcinoma, but this was minimal, low grade, and confined to the prostate gland, and thus it was felt to be unlikely to have metastasized to the bladder dome.
  • Adenocarcinoma arising in ectopic prostatic tissue is a rare finding and to our knowledge only 1 case has been previously described, occurring in the soft tissue adjacent to the prostate.
  • We report the first case of adenocarcinoma arising in ectopic prostatic tissue within the bladder.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Transitional Cell / pathology. Choristoma / pathology. Neoplasms, Multiple Primary / pathology. Prostate / pathology. Prostatic Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20807045.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Sato KT, Lewandowski RJ, Mulcahy MF, Atassi B, Ryu RK, Gates VL, Nemcek AA Jr, Barakat O, Benson A 3rd, Mandal R, Talamonti M, Wong CY, Miller FH, Newman SB, Shaw JM, Thurston KG, Omary RA, Salem R: Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres--safety, efficacy, and survival. Radiology; 2008 May;247(2):507-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary sites (origins) included colon, breast, neuroendocrine, pancreas, lung, cholangiocarcinoma, melanoma, renal, esophageal, ovary, adenocarcinoma of unknown primary, lymphoma, gastric, duodenal, bladder, angiosarcoma, squamous cell carcinoma, thyroid, adrenal, and parotid.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • (PMID = 18349311.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00532740
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


17. Bedaiwy MA, Hussein MR, Biscotti C, Falcone T: Pelvic endometriosis is rarely associated with ovarian borderline tumours, cytologic and architectural atypia: a clinicopathologic study. Pathol Oncol Res; 2009 Mar;15(1):81-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometriotic foci, especially ovarian ones, with epithelial cytologic atypia may be precursors of cancer.
  • Intraoperatively, the endometriotic lesions involved the ovaries (all cases); Cul de sac (four cases); urinary bladder (two cases); sigmoid colon, hemidiaphragms, and uterine vessels (one case each).
  • The endometriotic lesions were associated with uterine leiomyomas (two patients) and adenocarcinoma of the vagina (one patient).
  • In two cases, these features were sufficient for diagnosis of borderline Mullerian seromucinous tumours.
  • One patient had recurred with metastatic adenocarcinoma of the vault.

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Invest. 2002 Mar;32(3):199-206 [11895472.001]
  • [Cites] Cancer Sci. 2007 Mar;98(3):387-91 [17270029.001]
  • [Cites] Fertil Steril. 2005 Jul;84(1):12-5 [16009147.001]
  • [Cites] Mod Pathol. 2006 Dec;19(12):1615-23 [16980942.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jul;19(3):276-9 [10907178.001]
  • [Cites] J Reprod Immunol. 2005 Feb;65(1):55-63 [15694967.001]
  • [Cites] Hum Pathol. 2007 Jul;38(7):1074-80 [17442376.001]
  • [Cites] Ann N Y Acad Sci. 2002 Mar;955:281-92; discussion 293-5, 396-406 [11949955.001]
  • [Cites] Dis Markers. 2007;23(5-6):367-76 [18057520.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2007 Sep;134(1):83-6 [16844279.001]
  • [Cites] Arch Pathol Lab Med. 2003 Aug;127(8):1003-6 [12873175.001]
  • [Cites] Int J Gynecol Cancer. 2003 Jul-Aug;13(4):466-71 [12911723.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 2001 Jun;30(3):169-72 [11866970.001]
  • [Cites] Adv Anat Pathol. 2007 Jul;14(4):241-60 [17592255.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):379-81 [12451571.001]
  • [Cites] Hum Reprod. 2001 Dec;16(12):2668-71 [11726593.001]
  • [Cites] Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):239-42 [14505256.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Jan;82(1):85-7 [10192492.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:39-43 [11093060.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):42-51 [12496697.001]
  • [Cites] Fertil Steril. 2002 Oct;78(4):743-9 [12372450.001]
  • [Cites] Mod Pathol. 2006 Jan;19(1):83-9 [16258507.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 2006 Feb;41(2):111-3 [16640860.001]
  • [Cites] Am J Clin Pathol. 1999 Feb;111(2):248-51 [9930148.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:2-10 [11093055.001]
  • [Cites] Am J Obstet Gynecol. 2001 Jun;184(7):1407-11; discussion 1411-3 [11408860.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):138-44 [17227115.001]
  • [Cites] Int J Gynecol Cancer. 2003 May-Jun;13(3):376-80 [12801273.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Jul 1;109(1):97-101 [12818453.001]
  • [Cites] Pathol Res Pract. 2006;202(6):433-7 [16513291.001]
  • [Cites] Diagn Cytopathol. 1996 Jun;14(4):331-3 [8725135.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):345-51 [17581423.001]
  • [Cites] Ginekol Pol. 2001 May;72(5):268-72 [11526755.001]
  • [Cites] J Med Genet. 2006 Jan;43(1):84-90 [15930087.001]
  • [Cites] Int J Gynecol Pathol. 2006 Jul;25(3):223-9 [16810057.001]
  • [Cites] Reproduction. 2001 Apr;121(4):581-6 [11277878.001]
  • [Cites] Am J Surg Pathol. 2004 Mar;28(3):285-97 [15104291.001]
  • [Cites] Gynecol Obstet Invest. 2000;50 Suppl 1:44-50 [11093061.001]
  • [Cites] Am J Surg Pathol. 2007 Oct;31(10):1490-501 [17895749.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):401-6 [12352189.001]
  • [Cites] Med Electron Microsc. 2004 Jun;37(2):97-100 [15221651.001]
  • [Cites] Zhonghua Fu Chan Ke Za Zhi. 2000 Nov;35(11):667-9 [11218895.001]
  • [Cites] Am J Obstet Gynecol. 2004 Nov;191(5):1725-7 [15547552.001]
  • (PMID = 18575828.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


18. Hamasaki T, Kondo Y, Ogata Y, Yoshida K, Kimura G, Shimizu H, Nishimura T: Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder. Int J Clin Oncol; 2010 Feb;15(1):109-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced carcinoma of the prostatic urethra in a patient with marked response to chemotherapy, leading to preservation of the bladder.
  • Random bladder biopsies showed no malignancy, but a second TUR-P revealed urothelial carcinoma in the prostate and bladder neck.
  • Local control in the bladder was considered to be good, so total prostatectomy and retroperitoneal lymph node dissection was selected instead of total cystoprostatectomy.
  • Pathological findings of surgical specimens showed no residual carcinoma in the prostatic urethra or lymph nodes, although prostatic adenocarcinoma was recognized.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1996 Nov;48(5):703-10 [8911513.001]
  • [Cites] Am J Clin Pathol. 1963 Aug;40:183-9 [14060023.001]
  • [Cites] J Urol. 1973 Mar;109(3):457-60 [4348139.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):794-801 [11395558.001]
  • [Cites] Hinyokika Kiyo. 2000 Jul;46(7):495-8 [10965459.001]
  • [Cites] Urology. 1984 Dec;24(6):544-9 [6506393.001]
  • [Cites] J Urol. 1997 Aug;158(2):338-41 [9224298.001]
  • [Cites] Br J Urol. 1979 Dec;51(6):575-8 [534844.001]
  • [Cites] J Urol. 2005 Nov;174(5):1771-5; discussion 1775-6 [16217281.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1671-8 [10738226.001]
  • [Cites] Urology. 2007 Jan;69(1 Suppl):50-61 [17280908.001]
  • [Cites] Hinyokika Kiyo. 1970 Apr;16(4):157-61 [5463380.001]
  • (PMID = 20087614.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


19. Andreeva IuIu, Zavalishina LE, Frank GA: [Classification of urinary bladder tumors]. Arkh Patol; 2006 Sep-Oct;68(5):46-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Classification of urinary bladder tumors].
  • The paper outlines the topical aspects of the current classification of urinary bladder epithelial tumors.
  • Difficulties in the microscopic diagnosis of different types of urothelial carcinoma, the specific features of gradation and staging, and possibilities of differential diagnosis are presented.
  • [MeSH-major] Urinary Bladder Neoplasms / classification
  • [MeSH-minor] Adenocarcinoma, Clear Cell / classification. Adenocarcinoma, Clear Cell / pathology. Adenoma, Villous / classification. Adenoma, Villous / pathology. Carcinoma, Papillary / classification. Carcinoma, Papillary / pathology. Carcinoma, Small Cell / classification. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / classification. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / classification. Carcinoma, Transitional Cell / pathology. Humans. Urothelium / pathology. World Health Organization

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17144533.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Lectures
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


20. Rastinehad AR, Caplin DM, Ost MC, VanderBrink BA, Lobko I, Badlani GH, Weiss GH, Kavoussi LR, Siegel DN: Selective arterial prostatic embolization (SAPE) for refractory hematuria of prostatic origin. Urology; 2008 Feb;71(2):181-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 8 patients, 6 had a history of adenocarcinoma of the prostate (mean Gleason Grade 7, range 5 to 9); 4 were previously treated with external beam radiation.
  • One patient had gross hematuria develop 14 months after embolization that was attributed to a bladder tumor recurrence.
  • One patient with T4 prostate cancer had a rectovesical fistula develop 1 month after embolization.
  • CONCLUSIONS: SAPE results in cessation of refractory gross hematuria in patients with benign prostate hyperplasia and patients with prostate cancer previously treated with radiotherapy.
  • SAPE may be considered an effective treatment for gross hematuria in patients with refractory hematuria regardless of the cause (radiation, cancer and/or hyperplasia).
  • [MeSH-major] Adenocarcinoma / complications. Embolization, Therapeutic / methods. Hematuria / therapy. Prostate / blood supply. Prostatic Hyperplasia / complications. Prostatic Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18308078.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Jasperson KW, Blazer KR, Lowstuter K, Weitzel JN: Working through a diagnostic challenge: colonic polyposis, Amsterdam criteria, and a mismatch repair mutation. Fam Cancer; 2008;7(4):281-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The two most common causes of hereditary colorectal cancer are Lynch syndrome and familial adenomatous polyposis (FAP).
  • The phenotype of Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), is differentiated in part from FAP by the lack of profuse colonic polyposis.
  • Here we describe a proband who presented with greater than 50 adenomatous colonic polyps prior to developing cancer of the colon and urinary bladder, and a family history that fulfills the Amsterdam criteria.
  • Germline analyses of APC and MYH in the proband did not reveal any mutations.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenomatous Polyposis Coli / complications. Colonic Neoplasms / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / diagnosis. DNA-Binding Proteins
  • [MeSH-minor] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / genetics. Female. Genes, APC. Germ-Line Mutation. Humans. Middle Aged. Neoplasms, Multiple Primary / genetics. Pedigree. Phenotype. Urinary Bladder Neoplasms / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2002 Jul;97(7):1822-7 [12135043.001]
  • [Cites] Clin Genet. 1998 Oct;54(4):368-70 [9831355.001]
  • [Cites] Gut. 1997 Aug;41(2):235-8 [9301504.001]
  • [Cites] Gene. 2001 Jul 11;272(1-2):301-13 [11470537.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1453-6 [10348829.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):42-8 [14699485.001]
  • [Cites] Hum Mol Genet. 2001 Apr;10(7):721-33 [11257105.001]
  • [Cites] Hum Mutat. 2004 Mar;23(3):285 [14974087.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):807-14 [16557584.001]
  • [Cites] Int J Colorectal Dis. 2006 Jan;21(1):79-83 [16676398.001]
  • [Cites] J Med Genet. 1999 Oct;36(10 ):790-3 [10528862.001]
  • [Cites] Dis Colon Rectum. 1991 May;34(5):424-5 [2022152.001]
  • [Cites] Int J Colorectal Dis. 2006 Dec;21(8):847-50 [16525781.001]
  • [Cites] J Bacteriol. 1994 Sep;176(17):5393-400 [8071216.001]
  • [Cites] Hum Genet. 2006 Mar;119(1-2):206-11 [16408224.001]
  • [Cites] Gut. 2003 Jun;52(6):898-9 [12740349.001]
  • [Cites] Fam Cancer. 2007;6(1):43-51 [17039270.001]
  • [Cites] Fam Cancer. 2003;2(1):43-55 [14574166.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Oct;3(10):1022-8 [16234049.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11135-42 [11801590.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5908-13 [12732731.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):643-8 [11807791.001]
  • (PMID = 18176851.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / M01 RR000043; United States / NCI NIH HHS / CA / R25 CA085771; United States / NCRR NIH HHS / RR / M01 RR00043; United States / NCI NIH HHS / CA / R25 CA85771
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein
  •  go-up   go-down


22. Chan ES, Ng CF, Chui KL, Lo KL, Hou SM, Yip SK: Novel approach of laparoscopic transperitoneal en bloc resection of urachal tumor and umbilectomy with a comparison of various techniques. J Laparoendosc Adv Surg Tech A; 2009 Jun;19(3):423-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urachal carcinoma is a rare cancer that accounts for less than 1% of all bladder cancers.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy / methods. Umbilicus / surgery. Urachus / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19405800.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Terada T: Adenosquamous Carcinoma of the Stomach: Report of Two Cases. Gastroenterology Res; 2009 Feb;2(1):54-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathologically, the gastric tumor consisted of a mixture of adenocarcinoma (30% in area) and squamous cell carcinoma (70% in areas).
  • The adenocarcinoma consisted of signet ring cell carcinoma, poorly differentiated carcinoma, and tubular adenocarcinoma.
  • The gall bladder, lymph nodes and peritoneum showed metastases of adenocarcinoma.
  • Pathologically the gastric tumor was composed of a mixture of adenocarcinoma (10%) and squamous cell carcinoma (90%).
  • The adenocarcinoma element consisted of signet ring cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27956953.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Adenosquamous carcinoma / Histopathology / Stomach
  •  go-up   go-down


24. Giordano S, Taskinen S, Sankila A, Ala-Opas M: Adenocarcinoma in isolated rectal bladder after treatment of bladder exstrophy. Scand J Urol Nephrol; 2008;42(4):392-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma in isolated rectal bladder after treatment of bladder exstrophy.
  • We report the first Finnish patient with carcinoma in an augmented intestinal bladder, where urine and stools are not in contact.
  • The patient had undergone rectal bladder reconstruction at the age of 2 years because of bladder exstrophy.
  • When the patient was aged 46 years, a 2-cm, papillar, well-differentiated adenocarcinoma was detected and removed, preserving the rectal bladder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Bladder Exstrophy. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Child, Preschool. Humans. Male. Rectum / surgery. Urinary Bladder / abnormalities. Urinary Bladder / surgery

  • Genetic Alliance. consumer health - Exstrophy of the Bladder.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19230174.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


25. Numata K, Azuma K, Hashine K, Sumiyoshi Y: [Two cases of second bladder cancer after radiotherapy for prostate cancer]. Nihon Hinyokika Gakkai Zasshi; 2005 Mar;96(3):466-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of second bladder cancer after radiotherapy for prostate cancer].
  • Second cancer after radiotherapy is defined that more than five years have passed from radiotherapy for primary cancer in case of solid and different histological cancer and second cancer exists into or near radiotherapy area.
  • While it has been not frequent that a treatment for urological cancers causes second cancer, there is the possibility that second cancer increases by recent increase of radiotherapy for prostate cancer.
  • We report two cases of second bladder cancer after radiotherapy for prostate cancer.
  • It is important to take second cancer into consideration for long-term after the patients are treated with radiotherapy.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Transitional Cell / etiology. Neoplasms, Second Primary / etiology. Prostatic Neoplasms / radiotherapy. Radiotherapy / adverse effects. Urinary Bladder Neoplasms / etiology


26. Thirion P, Kelly C, Salib O, Moriarty M, O'Reilly D, Griffin M, Armstrong J: A randomised comparison of two brachytherapy devices for the treatment of uterine cervical carcinoma. Radiother Oncol; 2005 Mar;74(3):247-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on two-dimensional planning and the ICRU-38 bladder and rectal reference points, an advantage for the shielded Henschke applicator was demonstrated.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / instrumentation. Carcinoma, Squamous Cell / radiotherapy. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763304.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Ireland
  •  go-up   go-down


27. Zantl N, Gschwend JE: [Value of cystoprostatectomy in locally advanced prostate carcinoma]. Urologe A; 2008 Nov;47(11):1447-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • According to the literature cancer-specific 10-year survival rates are 38% or median cancer-specific survival lies between 24 and 31 months.
  • The role of neoadjuvant or adjuvant hormonal therapy, chemotherapy, or radiotherapy has not yet been defined.
  • Mostly after cystoprostatectomy due to locally advanced prostate carcinoma an ileal conduit is formed for urinary diversion, but also orthotopic neobladders or continent pouches are used.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Disease-Free Survival. Humans. Lymph Node Excision. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Palliative Care. Quality of Life. Salvage Therapy. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2005 Mar;173(3):781-3 [15711269.001]
  • [Cites] Eur Urol. 2007 Oct;52(4):1058-65 [17418938.001]
  • [Cites] BJU Int. 2005 Apr;95(6):794-8 [15794785.001]
  • [Cites] Urology. 1997 Oct;50(4):580-4 [9338735.001]
  • [Cites] Urology. 2005 Oct;66(4):824-9 [16230146.001]
  • [Cites] J Urol. 2005 Apr;173(4):1156-60 [15758726.001]
  • [Cites] J Urol. 2000 Jun;163(6):1771-4 [10799179.001]
  • [Cites] J Urol. 1998 Jul;160(1):29-33 [9628599.001]
  • [Cites] Urologe A. 2006 Oct;45(10):1260-5 [16983529.001]
  • [Cites] J Urol. 1988 Sep;140(3):544-9 [3411670.001]
  • [Cites] J Urol. 2005 Dec;174(6):2186-90 [16280761.001]
  • [Cites] J Urol. 1995 Jan;153(1):104-10 [7526002.001]
  • [Cites] Aktuelle Urol. 2003 Jul;34(4):259-61 [14566679.001]
  • [Cites] Am J Public Health. 2001 Jan;91(1):126-8 [11189804.001]
  • [Cites] Urologe A. 2004 Feb;43(2):172-7 [14991119.001]
  • [Cites] J Urol. 2003 Nov;170(5):1868-71 [14532795.001]
  • [Cites] Urologe A. 2006 Apr;45(4):474-81 [16465521.001]
  • [Cites] Urology. 1998 May;51(5):789-95 [9610593.001]
  • (PMID = 18810382.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Rozet F, Lesur G, Cathelineau X, Barret E, Smyth G, Soon S, Vallancien G: Oncological evaluation of prostate sparing cystectomy: the Montsouris long-term results. J Urol; 2008 Jun;179(6):2170-4; discussion 2174-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Prostate sparing cystectomy provides an alternative therapeutic option in highly selected patients with invasive bladder cancer who wish to avoid the significant functional side effects of traditional surgery.
  • Concern exists regarding the oncological safety of this technique especially with regard to the presence of prostatic urothelial cancer and incidental prostate adenocarcinoma.
  • Of 6 patients found to have prostate adenocarcinoma in transurethral prostate resection specimens 1 was treated with high intensity focused ultrasound and 5 were followed with active surveillance, 2 of whom later died of bladder cancer.
  • With appropriate screening the risk of a clinically significant prostate cancer appears to be low.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423740.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Suttmann H, Holl-Ulrich K, Peter M, Kausch I, Doehn C, Jocham D: Mesonephroid adenocarcinoma arising from mesonephroid metaplasia of the urinary bladder. Urology; 2006 Apr;67(4):846.e7-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesonephroid adenocarcinoma arising from mesonephroid metaplasia of the urinary bladder.
  • We present a rare case of mesonephroid adenocarcinoma arising from mesonephroid metaplasia of the urinary bladder.
  • For the first time, the unique histopathologic features in this patient provide evidence for the theory that vesical mesonephroid adenocarcinoma might be a highly aggressive metaplastic variant of urothelial carcinoma that should be treated accordingly.
  • [MeSH-major] Adenocarcinoma / pathology. Urinary Bladder / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566962.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Sönmez NC, Coşkun B, Arisan S, Güney S, Dalkiliç A: Early penile metastasis from primary bladder cancer as the first systemic manifestation: a case report. Cases J; 2009;2:7281
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early penile metastasis from primary bladder cancer as the first systemic manifestation: a case report.
  • 77% of the metastases are originated from the pelvic region; prostate and bladder are the most frequent primary locations.
  • Diagnosis is usually made by biopsy and also non invasive methods as MRI or colour-coded duplex ultrasonography.
  • Despite these alternatives prognosis is usually poor.We present a case of urethelial carcinoma of the bladder and coincidental prostate adenocarcinoma with penile metastasis which is presented with priapism 6 months after radical cystectomy as the first systemic manifestation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1998 May;68(1):51-9 [9610664.001]
  • [Cites] Australas Radiol. 1999 Aug;43(3):378-81 [10901942.001]
  • [Cites] Int Semin Surg Oncol. 2006;3:33 [17032461.001]
  • [Cites] BMC Cancer. 2004 Dec 3;4:90 [15575962.001]
  • [Cites] Urol Int. 2006;76(2):118-21 [16493210.001]
  • [Cites] Urology. 2003 Jul;62(1):145 [12837452.001]
  • (PMID = 20184686.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827083
  •  go-up   go-down


31. Hasegawa Y, Kato Y, Wakita T, Hayashi N, Tsukamoto K: [Carcinoma of the urachus: a case report]. Hinyokika Kiyo; 2005 Mar;51(3):191-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cystoscopy revealed a broad-stalk, nonpapillary tumor at the urinary bladder dome, and cold-punch biopsy proved it to be a mucus-producing adenocarcinoma.
  • Abdominal managnetic resonance imaging demonstrated a tumor extending from the umbilicus to the bladder dome, and chest computed tomography (CT) demonstrated a small lung tumor with calcification.
  • Examination of the upper gostroinstestinal tract, barium enema, and colon fiberscopy did not reveal abnormalities.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urachus

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852675.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


32. Emerson RE, Cheng L: Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review. Anal Quant Cytol Histol; 2005 Dec;27(6):301-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical markers in the evaluation of tumors of the urinary bladder: a review.
  • The clinical utility of immunohistochemistry in the diagnosis of tumors of the urinary bladder is well established.
  • With recent advances in molecular biology and novel technologies, several biomarkers have emerged as important adjuncts in the diagnosis of lesions of the bladder.
  • When used in conjunction with careful histologic examination, immunohistochemistry can be a valuable aid in classifying adenocarcinoma presenting in the bladder and mesenchymal lesions of the bladder and in establishing the urothelial origin of a metastatic tumor.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Anal Quant Cytol Histol. 2007 Apr;29(2):121-2 [17484276.001]
  • [CommentIn] Anal Quant Cytol Histol. 2007 Dec;29(6):380-2 [18225396.001]
  • (PMID = 16450787.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 137
  •  go-up   go-down


33. Hayashi T, Ujike T, Yamamoto Y, Kamoto A, Nin M, Nishimura K, Miyoshi S, Kawano K: [Female urethral adenocarcinoma with urinary retention: a case report]. Hinyokika Kiyo; 2009 Jul;55(7):429-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Female urethral adenocarcinoma with urinary retention: a case report].
  • A 57-year-old woman presented with urinary retention.
  • Intravenous pyelography demonstrated the filling defect of bladder.
  • Magnetic resonance imaging revealed the mass that had invaded bladder neck at dorsal side of urethra.
  • Pathological examination of transvaginal needle biopsy suggested well-differentiated adenocarcinoma.
  • Pathological diagnosis was urethral adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Urethral Neoplasms / complications. Urinary Retention / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19673433.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


34. Yenilmez A, Donmez T, Acikalin MF, Kale M: Adenonocarcinoma of the urinary bladder mimicking simple ureterocele: a case report. Int Urol Nephrol; 2007;39(2):465-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenonocarcinoma of the urinary bladder mimicking simple ureterocele: a case report.
  • We report a case of adenocarcinoma of the urinary bladder, mimicking simple ureterocele in a 55-year-old man, presenting irritative bladder symptoms.
  • Transurethral biopsy of the lesion was performed and pathological examination revealed a muscle-invasive adenocarcinoma.
  • The patient underwent radical cystectomy and urinary diversion.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ureterocele / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Can Assoc Radiol. 1972 Dec;23 (4):284-6 [4646901.001]
  • [Cites] J Urol. 1974 Jan;111(1):36-7 [4813551.001]
  • [Cites] Br J Urol. 1987 Sep;60(3):271-2 [3676678.001]
  • [Cites] J Urol. 1977 May;117(5):557-61 [870705.001]
  • [Cites] Urology. 1984 Aug;24(2):175-7 [6464253.001]
  • [Cites] Urology. 1981 Jul;18(1):91 [7257050.001]
  • (PMID = 17171419.001).
  • [ISSN] 0301-1623
  • [Journal-full-title] International urology and nephrology
  • [ISO-abbreviation] Int Urol Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


35. Wilhelm TJ, Knoll T, Weisser G, Grobholz R, Köhrmann KU, Post S: Urothelial carcinoma of the ureter, giant rectal stone and sigmoid carcinoma 55 years after ureterosigmoidostomy. Scand J Urol Nephrol; 2006;40(2):172-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a unique accumulation of complications 55 years after ureterosigmoidostomy for bladder exstrophy and discuss possible implications for follow-up strategies.
  • [MeSH-major] Calculi / pathology. Colonic Neoplasms / pathology. Rectal Diseases / pathology. Ureteral Neoplasms / pathology. Urinary Bladder / abnormalities. Urinary Bladder Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Humans. Ileum / surgery. Male. Middle Aged. Reconstructive Surgical Procedures. Sigmoidoscopy. Tomography, X-Ray Computed. Ureterostomy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608820.001).
  • [ISSN] 0036-5599
  • [Journal-full-title] Scandinavian journal of urology and nephrology
  • [ISO-abbreviation] Scand. J. Urol. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


36. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res; 2005 Mar 1;65(5):1642-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sequenced the tyrosine kinase domain of HER2 in 671 primary non-small cell lung cancers (NSCLC), 80 NSCLC cell lines, and 55 SCLCs and other neuroendocrine lung tumors as well as 85 other epithelial cancers (breast, bladder, prostate, and colorectal cancers) and compared the mutational status with clinicopathologic features and the presence of EGFR or KRAS mutations.
  • Only one adenocarcinoma cell line (NCI-H1781) had a mutation.
  • HER2 mutations were significantly more frequent in never smokers (3.2%, 8 of 248; P=0.02) and adenocarcinoma histology (2.8%, 11 of 394; P=0.003).
  • In 394 adenocarcinoma cases, HER2 mutations preferentially targeted Oriental ethnicity (3.9%) compared with other ethnicities (0.7%), female gender (3.6%) compared with male gender (1.9%) and never smokers (4.1%) compared with smokers (1.4%).
  • EGFR, HER2, and KRAS mutations are mutually exclusive, suggesting different pathways to lung cancer in smokers and never smokers.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, erbB-2 / genetics. Genes, ras / genetics. Lung Neoplasms / genetics. Mutation / genetics


37. Balachandra B, Swanson PE, Upton MP, Yeh MM: Adenocarcinoma arising in a gastrocystoplasty. J Clin Pathol; 2007 Jan;60(1):85-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising in a gastrocystoplasty.
  • Gastrocystoplasty is a form of surgical bladder augmentation or neobladder used to restore bladder capacity and compliance in children and in patients with neurogenic bladder.
  • Other forms of bladder augmentation include ileocystoplasty and colocystoplasty.
  • However, the first case of adenocarcinoma arising in the setting of a gastrocystoplasty is reported.
  • [MeSH-major] Adenocarcinoma / etiology. Stomach / transplantation. Urinary Bladder Neoplasms / etiology. Urinary Bladder, Neurogenic / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2002 Aug;168(2):698-701; discussion 701 [12131353.001]
  • [Cites] J Urol. 1999 Sep;162(3 Pt 2):1122-5 [10458445.001]
  • [Cites] Hum Pathol. 1983 Nov;14(11):931-68 [6629368.001]
  • [Cites] J Urol. 1990 Apr;143(4):671-8 [2179579.001]
  • [Cites] J Urol. 1990 Nov;144(5):1283-7 [2231914.001]
  • [Cites] BMJ. 1991 Jun 1;302(6788):1302-5 [2059685.001]
  • [Cites] J Urol. 1993 Apr;149(4):731-4 [8455232.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 2):730-3 [8326635.001]
  • [Cites] Hum Pathol. 1994 Mar;25(3):221-6 [7512070.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 1):473-4 [8015094.001]
  • [Cites] J Urol. 1994 Aug;152(2 Pt 2):720-4 [8022004.001]
  • [Cites] Hum Pathol. 1994 Oct;25(10):982-93 [7927321.001]
  • [Cites] J Pediatr Surg. 1997 Dec;32(12):1757-8 [9434020.001]
  • [Cites] J Pediatr Surg. 1999 Apr;34(4):532-5 [10235315.001]
  • [Cites] Int J Surg Pathol. 2003 Apr;11(2):143-7 [12754637.001]
  • (PMID = 17213351.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1860596
  •  go-up   go-down


38. Kurosaka S, Irie A, Mizoguchi H, Okuno N, Iwabuchi K, Baba S: Advanced clear-cell adenocarcinoma of the bladder successfully treated by radical surgery with adjuvant chemoradiotherapy. Int J Clin Oncol; 2005 Oct;10(5):362-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced clear-cell adenocarcinoma of the bladder successfully treated by radical surgery with adjuvant chemoradiotherapy.
  • The tumor seemed to have arisen from the bladder or urethra, and bilateral iliac lymphadenopathy was seen.
  • Histopathological examination of the biopsy specimens showed clear-cell adenocarcinoma.
  • Macroscopically, the tumor had arisen from the trigone of the bladder, and histopathological examination of the tumor revealed adenocarcinoma exhibiting solid clear cells with glandular and papillary patterns.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / surgery. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Urol. 2002 Aug;9(8):467-9 [12225345.001]
  • [Cites] Urol Int. 2003;71(2):228-30 [12890970.001]
  • [Cites] Eur J Gynaecol Oncol. 1996;17(1):13-6 [8750509.001]
  • [Cites] Cancer Lett. 2001 Jan 10;162(1):39-48 [11121861.001]
  • [Cites] Mod Pathol. 1993 Mar;6(2):225-8 [8483895.001]
  • [Cites] J Urol. 1968 Oct;100(4):466-9 [5677385.001]
  • [Cites] Histopathology. 1990 Jun;16(6):601-4 [2376401.001]
  • [Cites] Urology. 1984 Mar;23(3):303-4 [6199882.001]
  • [Cites] J Urol. 1990 Jan;143(1):122-5 [2294240.001]
  • (PMID = 16247666.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


39. Koo VS, Lynn NN, Saxby MF: Radical exenteration surgery is curative in locally advance mucinous prostatic adenocarcinoma involving bladder and rectum. J Surg Case Rep; 2010;2010(4):6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical exenteration surgery is curative in locally advance mucinous prostatic adenocarcinoma involving bladder and rectum.
  • The management of mucinous prostatic adenocarcinoma include hormonal treatment, radiotherapy and radical prostatectomy with variable long-term outcome.
  • We report a 59 year old man with advanced mucinous prostatic adenocarcinoma involving almost the entire bladder and had failed treatment with hormonal and radiotherapy, but subsequently underwent radical pelvic exenteration surgery that resulted in long-term cure.
  • He remains alive, his PSA remains undetectable and his surveillance CT scans did not show any evidence of recurrence after 11 years post-surgery.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © JSCR.
  • (PMID = 24946309.001).
  • [ISSN] 2042-8812
  • [Journal-full-title] Journal of surgical case reports
  • [ISO-abbreviation] J Surg Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3649112
  •  go-up   go-down


40. Wood B, Sterrett G, Frost F, Swarbrick N: Diagnosis of extramammary malignancy metastatic to the breast by fine needle biopsy. Pathology; 2008 Jun;40(4):345-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of extramammary malignancy metastatic to the breast by fine needle biopsy.
  • RESULTS: The 32 cases included metastases from a wide range of sites, including cutaneous melanoma (10), lung (8), non-Hodgkin's lymphoma (5), soft tissue (4), colon (2), endometrium, ovary and bladder.
  • Only one case was initially mistaken for a primary tumour, in this case the history of prior malignancy with systemic metastases was not provided to the reporting pathologist.
  • The cytological features allow metastatic disease to be suspected in half of the cases, although in the others, particularly patients with metastatic adenocarcinoma, diagnosis without recourse to immunohistochemistry is difficult or impossible.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Lung Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Melanoma / secondary. Skin Neoplasms / pathology


41. Norkus D, Miller A, Kurtinaitis J, Haverkamp U, Popov S, Prott FJ, Valuckas KP: A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity. Strahlenther Onkol; 2009 Nov;185(11):715-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional external-beam radiotherapy for localized prostate adenocarcinoma : a report on acute toxicity.
  • PURPOSE: To compare acute gastrointestinal (GI) and genitourinary (GU) toxicity between patient groups with localized prostate adenocarcinoma, treated with conventionally fractionated (CFRT) and hypofractionated (HFRT) three-dimensional conformal external-beam radiotherapy (3D-CRT).
  • [MeSH-major] Adenocarcinoma / radiotherapy. Dose Fractionation. Gastrointestinal Tract / radiation effects. Prostatic Neoplasms / radiotherapy. Radiation Injuries / etiology. Radiotherapy Planning, Computer-Assisted / methods. Urogenital System / radiation effects
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Disease-Free Survival. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Lithuania. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Prostate / radiation effects. Prostate-Specific Antigen / blood. Radiotherapy Dosage. Radiotherapy, Conformal. Rectum / radiation effects. Seminal Vesicles / radiation effects. Urinary Bladder / radiation effects

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Strahlenther Onkol. 2009 Nov;185(11):722-3 [19899004.001]
  • [Cites] J Urol. 2001 Sep;166(3):876-81 [11490237.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1424-30 [17544601.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1099-105 [17336216.001]
  • [Cites] Cancer J. 2003 Jul-Aug;9(4):268-76 [12967137.001]
  • [Cites] Strahlenther Onkol. 2008 Dec;184(12 ):668-73 [19107348.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):518-26 [16242256.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):943-55 [12605972.001]
  • [Cites] Radiother Oncol. 2006 Jul;80(1):78-81 [16828910.001]
  • [Cites] Strahlenther Onkol. 2007 Nov;183(11):610-6 [17960336.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183 Spec No 2:14-5 [18166999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Nov 1;72 (3):770-6 [18375075.001]
  • [Cites] Radiother Oncol. 2003 Nov;69(2):161-8 [14643953.001]
  • [Cites] Strahlenther Onkol. 2007 Jun;183(6):321-6 [17520186.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1084-9 [17606331.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):534-43 [16246497.001]
  • [Cites] Strahlenther Onkol. 2007 Feb;183(2):57-62 [17294108.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):6-13 [11777617.001]
  • [Cites] Strahlenther Onkol. 2008 Dec;184(12 ):674-8 [19107349.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Radiat Oncol. 2007 Aug 08;2:29 [17686162.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):988-93 [11704322.001]
  • (PMID = 19899003.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


42. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley JT, Denmeade SR: A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst; 2007 Mar 7;99(5):376-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Most men will develop prostatic abnormalities, such as benign prostatic hyperplasia (BPH) or prostate cancer, as they age.
  • The viability of the prostate adenocarcinoma cell lines LNCaP, PC-3, CWR22H, and DU145 and the bladder cancer cell line TSU after treatment with PA or PRX302 in the presence or absence of purified PSA was assayed.
  • Single intratumoral injections of PRX302 produced substantial and often complete regression of PSA-secreting human prostate cancer xenografts (5 microg dose, complete regression in 6 of 26 mice bearing LNCap or CWR22H xenografts [23%]; 10 microg dose, complete regression in 10 of 26 mice [38.5%]) but not PSA-null bladder cancer xenografts.

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Urol. 2006 Jun;49(6):970-8; discussion 978 [16481092.001]
  • [Cites] Urology. 1995 Sep;46(3 Suppl A):41-6 [7544516.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] BJU Int. 2004 Nov;94(7):1031-6 [15541122.001]
  • [Cites] Nat Rev Cancer. 2004 Nov;4(11):876-90 [15516960.001]
  • [Cites] Urology. 1999 Sep;54(3):411-5 [10475344.001]
  • [Cites] J Biol Chem. 1998 Dec 4;273(49):32656-61 [9830006.001]
  • [Cites] JAMA. 1999 May 5;281(17):1591-7 [10235151.001]
  • [Cites] Cancer J Sci Am. 1998 May;4 Suppl 1:S15-21 [9619266.001]
  • [Cites] J Struct Biol. 1998;121(2):92-100 [9615432.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4924-30 [9354459.001]
  • [Cites] FEMS Microbiol Lett. 1997 Apr 15;149(2):157-63 [9141656.001]
  • [Cites] Trends Microbiol. 2000 Apr;8(4):168-72 [10754575.001]
  • [Cites] Anim Reprod Sci. 2000 Jul 2;60-61:405-15 [10844211.001]
  • [Cites] Prostate. 2001 Jun 15;48(1):1-6 [11391681.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6340-4 [11522622.001]
  • [Cites] J Urol. 2003 Feb;169(2):517-23 [12544300.001]
  • [Cites] Prostate. 2003 Jun 15;56(1):45-53 [12746846.001]
  • [Cites] Curr Urol Rep. 2003 Jun;4(3):211-5 [12756084.001]
  • [Cites] J Natl Cancer Inst. 2003 Jul 2;95(13):990-1000 [12837835.001]
  • [Cites] Urology. 2003 Nov;62(5 Suppl 1):27-33 [14607215.001]
  • [Cites] BJU Int. 2004 Jan;93(1):14-8 [14678360.001]
  • [Cites] Urol Int. 2004;72(1):32-9 [14730163.001]
  • [Cites] J Cell Biochem. 2004 Feb 15;91(3):528-39 [14755683.001]
  • [Cites] J Urol. 2004 Jul;172(1):20-6 [15201730.001]
  • [Cites] J Urol. 2004 Sep;172(3):910-4 [15310996.001]
  • [Cites] Curr Treat Options Oncol. 2004 Oct;5(5):357-65 [15341674.001]
  • [Cites] Prog Clin Biol Res. 1980;37:115-32 [7384082.001]
  • [Cites] Acta Oncol. 1991;30(2):231-7 [2029413.001]
  • [Cites] Prostate. 1992;20(2):105-11 [1372426.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):394-8 [8433392.001]
  • [Cites] Appl Environ Microbiol. 1993 Nov;59(11):3625-33 [8285670.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2455-62 [7538903.001]
  • [Cites] Curr Pharm Des. 2006;12(7):775-83 [16515494.001]
  • (PMID = 17341729.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P50CA58236
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Bacterial Toxins; 0 / PRX302; 0 / Pore Forming Cytotoxic Proteins; 0 / Prodrugs; 0 / proaerolysin; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS401596; NLM/ PMC4133793
  •  go-up   go-down


43. Venizelos I, Tamiolakis D, Petrakis G: Primary combined carcinoid and adenocarcinoma of the ileum associated with transitional carcinoma of the bladder. Single case report. Rev Esp Enferm Dig; 2007 Mar;99(3):145-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary combined carcinoid and adenocarcinoma of the ileum associated with transitional carcinoma of the bladder. Single case report.
  • Composite neoplasms, carcinoid and adenocarcinoma have been reported to occur in several parts of the body, including the stomach, ampulla of Vater, large bowel, lung, and urinary bladder.
  • Here we report a case of a 74-year-old male with a composite carcinoid-adenocarcinoma of the ileum associated with a transitional cell carcinoma of the bladder.
  • The microscopical examination of the composite tumor showed an admixture of typical carcinoid tumor and moderately a differentiated adenocarcinoma.
  • A review of the literature revealed that this is the first reported case of composite carcinoid-adenocarcinoma of the ileum associated with transitional cell carcinoma of the urinary bladder.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoid Tumor / pathology. Carcinoma, Transitional Cell / pathology. Ileal Neoplasms / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Esp Enferm Dig. 2007 Nov;99(11):682. Venizelos, I D [corrected to Venizelos, I]; Lambropoulou, M [removed]; Constantinidis, T [removed]; Alexiadis, G [removed]; Papadopoulos, N [removed]
  • (PMID = 17516827.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


44. Sugimori K, Kobayashi K, Hayashi M, Sakai N, Sasaki M, Koshino Y: Leptomeningeal carcinomatosis from urinary bladder adenocarcinoma: a clinicopathological case study. Neuropathology; 2005 Mar;25(1):89-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis from urinary bladder adenocarcinoma: a clinicopathological case study.
  • We report a 73-year-old male patient with leptomeningeal metastasis from urinary bladder adenocarcinoma.
  • Meningeal carcinomatosis was detected 5 days before his death, but the primary site of the malignant tumor could not be determined.
  • Necropsy revealed leptomeningeal infiltration of many adenocarcinoma cells that covered the cerebrum.
  • Meningeal carcinomatosis from urinary bladder adenocarcinoma is extremely rare and up-regulation of the adhesion molecules in the meningeal adenocarcinoma was confirmed.
  • [MeSH-major] Adenocarcinoma / secondary. Meningeal Neoplasms / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15822823.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Vascular Cell Adhesion Molecule-1; 68238-35-7 / Keratins
  •  go-up   go-down


45. Ogren M, Bergqvist D, Wåhlander K, Eriksson H, Sternby NH: Trousseau's syndrome - what is the evidence? A population-based autopsy study. Thromb Haemost; 2006 Mar;95(3):541-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite numerous studies documenting the association between cancer and venous thromboembolism (VTE), the reason for the excessive risk in certain cancers remains obscure.
  • No large-scale studies have yet investigated the independent effects of cancer type, site and growth pattern.
  • The relationship between cancer and PE was evaluated with logistic regression.
  • Forty-two per cent of pancreatic cancer patients had PE (OR 2.55; 95% CI 2.10-3.09) (p<0.001); gall bladder, gastric, colorectal and pulmonary adenocarcinomas were similarly independently associated with PE.
  • In comparison with squamous cell lung cancer, patients with pulmonary adenocarcinoma had 1.65 times higher odds for PE (95% CI 1.20-2.29).
  • Adenocarcinoma and metastatic cancer were independently associated with PE risk (OR 1.27; 95% CI 1.16-1.40; p<0.001, and OR 1.10;95% CI 1.01-1.20; p=0.024, respectively) but when controlling for cancer type and spread, pancreatic cancer was still associated with an OR of 2.10 (95% CI 1.71-2.58) of PE (p<0.001).
  • We conclude that the risk of PE in cancer patients depends not only on the cancer site and spread but also on the histological type.
  • The excess independent risk in pancreatic cancer is intriguing and should warrant further research.
  • [MeSH-major] Adenocarcinoma / complications. Gallbladder Neoplasms / complications. Pancreatic Neoplasms / complications. Pulmonary Embolism / etiology. Stomach Neoplasms / complications


46. Kaouk JH, Goel RK, White MA, White WM, Autorino R, Haber GP, Campbell SC: Laparoendoscopic single-site radical cystectomy and pelvic lymph node dissection: initial experience and 2-year follow-up. Urology; 2010 Oct;76(4):857-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of laparoendoscopic single-site surgery and its application to urothelial malignancy has not been previously evaluated.
  • All patients underwent extracorporeal urinary diversion by way of extension of the umbilical port site.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Endoscopy / methods. Laparoscopy / methods. Lymph Node Excision / methods. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Aged. Aged, 80 and over. Equipment Design. Feasibility Studies. Female. Follow-Up Studies. Humans. Laparoscopes. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / surgery. Pelvis. Prostatic Neoplasms / pathology. Prostatic Neoplasms / surgery. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20646750.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Obando JA, Samii JM, Yasrebi M: A case of two synchronous primary lung tumors demonstrated by FDG positron emission tomography. Clin Nucl Med; 2008 Nov;33(11):775-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacokinetics. Lung Neoplasms / radionuclide imaging. Neoplasms, Multiple Primary / radionuclide imaging
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Humans. Male. Positron-Emission Tomography / methods. Prostatic Neoplasms / pathology. Radiopharmaceuticals / pharmacokinetics. Urinary Bladder Neoplasms / pathology. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936611.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


48. Raabe NK, Lilleby W, Tafjord G, Aström L: [High dose rate brachytherapy in prostate cancer in Norway]. Tidsskr Nor Laegeforen; 2008 May 29;128(11):1275-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High dose rate brachytherapy in prostate cancer in Norway].
  • Brachytherapy with a high dose rate permits an escalation of dose within the prostate without increasing the risk of side effects to the surrounding rectum and bladder.
  • This article presents a study of the first 100 patients in Norway with localized/locally advanced prostate cancer treated with high dose-rate brachytherapy combined with external radiotherapy.
  • High dose rate brachytherapy is indicated in patients with prostate cancer of an intermediate or high risk or if a radiation dose with a full external beam proposes a hazard to the patient.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Prostatic Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18511969.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


49. Kwiatkowski M, Paśnik K, Orłowski M, Furga P: [Therapeutic and diagnostic problems in a patient with a pelvic tumour--case report]. Pol Merkur Lekarski; 2009 May;26(155):496-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal cancer has become the commonest form of cancer in gastrointestinal (GI) tract and nowadays it is the second cause of death among all malignant tumours.
  • Bladder cancer is the fourth commonest tumour in males and eighth in females.
  • Despite repeated colon and bladder biopsies no malignancy was found.
  • The results of imaging investigations suggested a bladder-derived tumour (from a bladder diverticulum or persisting urachus).
  • The diagnosis confirmed in histological examination was adenocarcinoma of the colon.
  • The article presents successive stages of diagnosis and therapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Colonic Neoplasms / diagnosis. Colonic Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Humans. Male. Urinary Bladder Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606709.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


50. Dickson BC, Fornasier VL, Streutker CJ, Stewart RJ: Ureteric obstruction: an unusual presentation of metastatic colon carcinoma. Can J Urol; 2007 Apr;14(2):3526-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present the case of a 78-year-old male who presented to clinic for follow-up of a papillary transitional cell carcinoma of the urinary bladder.
  • Notably, the patient also had a history of colorectal resection for an adenocarcinoma.
  • Upon surgical resection the lesion was found to be an adenocarcinoma, morphologically consistent with a metastasis from the patient's primary colonic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Ureteral Neoplasms / secondary. Ureteral Obstruction / etiology
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / pathology. Humans. Male. Neoplasms, Second Primary. Urinary Bladder Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466162.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


51. Srivastava K, Singh S, Srivastava M, Srivastava AN: Incisional skin metastasis of a squamous cell cervical carcinoma 3.5 years after radical treatment--a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1183-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most commonly metastatic skin incisional cancers have been reported with cancers of colon, kidney, and bladder.
  • It has been reported in few patients with adenocarcinoma and poorly differentiated histopathology, more so at drain site postoperatively.
  • She received salvage chemotherapy; however, she did not show any response and finally succumbed to the disease.


52. Shiwani MH: Surgical management of gall bladder carcinoma. J Pak Med Assoc; 2007 Feb;57(2):87-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of gall bladder carcinoma.
  • CaGB is a rare form of cancer and its association with gallstone disease should be recognised.
  • Although overall prognosis is poor, early diagnosis of CaGB and radical surgery provides better outcome.
  • [MeSH-major] Adenocarcinoma / surgery. Gallbladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17370792.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Pakistan
  • [Number-of-references] 17
  •  go-up   go-down


53. Weizer AZ, Shah RB, Lee CT, Gilbert SM, Daignault S, Montie JE, Wood DP Jr: Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol; 2007 Nov-Dec;25(6):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Prostate capsule sparing cystectomy has been performed in conjunction with orthotopic diversion to preserve sexual function and improve urinary control.
  • Because concerns remain regarding incomplete surgical resection, we evaluated the risk of urothelial and prostate cancer in a series of patients undergoing radical cystoprostatectomy.
  • METHODS: A total of 35 men undergoing radical cystoprostatectomy (August 2003-August 2005) had separate submission of the prostate peripheral zone/capsule from the prostate adenoma and bladder after surgery.
  • These specimens were evaluated for bladder and prostate cancer grade, stage, and largest diameter of prostate cancer.
  • RESULTS: Of patients, 57% had cancer involving the prostate at radical cystoprostatectomy.
  • Prostate adenocarcinoma was evident in 16 of 35 (47%) patients, with a majority involving the prostate peripheral zone/capsule (43%).
  • There were 4 patients (11%) who had clinically significant prostate cancer (Gleason sum >6 or tumor volume >0.5 cm(3)).
  • Patients with prostate cancer were significantly older than patients without prostate cancer (P = 0.01).
  • CONCLUSIONS: No clinical variable can confidently predict patients with prostate cancer involving the prostate.
  • Because a majority of patients undergoing radical cystoprostatectomy have cancer involving their prostate, preoperative evaluation with prostatic urethral and prostate biopsy may be useful to guide patient selection for prostate capsule sparing cystectomy.
  • [MeSH-major] Cystectomy / methods. Prostate / pathology. Prostatectomy / methods. Prostatic Neoplasms / surgery. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18047952.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Pagano S, Ruggeri P, Rovellini P, Bottanelli A: The anterior ileal conduit: results of 100 consecutive cases. J Urol; 2005 Sep;174(3):959-62; discussion 962
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The ileal conduit of Bricker is still widely used for urinary diversion after radical cystectomy for bladder carcinoma.
  • RESULTS: A total of 100 consecutive patients after radical cystectomy for bladder cancer had anterior ileal conduit.
  • The surgical revision and the treatment of ureteroileal stenoses with anterograde percutaneous ureteral stenting were not complicated procedures.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / surgery. Cystectomy. Postoperative Complications / etiology. Urinary Bladder Neoplasms / surgery. Urinary Diversion / methods

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16094008.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Ferrari A, Botrugno I, Bombelli E, Dominioni T, Cavazzi E, Dionigi P: Colonoscopy is mandatory after Streptococcus bovis endocarditis: a lesson still not learned. Case report. World J Surg Oncol; 2008;6:49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colonoscopy is mandatory after Streptococcus bovis endocarditis: a lesson still not learned. Case report.
  • BACKGROUND: Even though the relationship between certain bacterial infections and neoplastic lesions of the colon is well-recognized, this knowledge has not been sufficiently translated into routine practice yet.
  • Preoperative colonoscopy, staging exams and subsequent surgery demonstrated a stenotic adenocarcinoma of the sigmoid colon, invading the left urinary tract and the homolateral bladder wall, with regional lymph nodes involvement and massive bilobar liver metastases (T4N1M1).
  • After Hartmann's rectosigmoidectomy and despite systemic chemotherapy, a rapid progression occurred and the patient survived for only 5 months after diagnosis.
  • Five years before detecting this advanced colonic cancer, the patient underwent aortic valve replacement due to a severe Streptococcus bovis endocarditis.
  • CONCLUSION: As this case illustrates, in the unusual setting of a Streptococcus bovis infection, it is necessary to timely and carefully rule out occult colon cancer and other malignancies during hospitalization and, if a tumor is not found, to schedule endoscopic follow-up.
  • Rigorous application of these recommendations in the case described would have likely led to an earlier diagnosis of cancer and maybe saved the patient's life.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Colonoscopy. Endocarditis, Bacterial / etiology. Streptococcal Infections / etiology. Streptococcus bovis

  • Genetic Alliance. consumer health - Endocarditis.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Streptococcal Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Jun;211(6):786-91; discussion 791-2 [2357141.001]
  • [Cites] Eur Heart J. 1995 Dec;16(12):1975-80 [8682035.001]
  • [Cites] J Laryngol Otol. 1997 Jul;111(7):666-8 [9282212.001]
  • [Cites] J Clin Pathol. 1998 Jun;51(6):473-4 [9771449.001]
  • [Cites] J Med Assoc State Ala. 1951 Dec;21(6):162-6 [14880846.001]
  • [Cites] Clin Infect Dis. 2005 Apr 1;40(7):1070-1 [15825011.001]
  • [Cites] Dis Colon Rectum. 2006 Aug;49(8):1223-7 [16845563.001]
  • [Cites] Int J Cancer. 2006 Nov 1;119(9):2127-35 [16841330.001]
  • [Cites] Singapore Med J. 2007 Feb;48(2):e43-5 [17304377.001]
  • [Cites] Dig Dis Sci. 2007 Sep;52(9):2336-9 [17443405.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):753-6 [10753212.001]
  • [Cites] Rheumatology (Oxford). 2000 Mar;39(3):338-9 [10788550.001]
  • [Cites] Int J Syst Evol Microbiol. 2003 May;53(Pt 3):631-45 [12807180.001]
  • [Cites] Clin Infect Dis. 2004 May 15;38(10):1394-400 [15156477.001]
  • [Cites] Arch Surg. 2004 Jul;139(7):760-5 [15249410.001]
  • [Cites] Ann Surg. 1974 Feb;179(2):190-1 [4204268.001]
  • [Cites] N Engl J Med. 1977 Oct 13;297(15):800-2 [408687.001]
  • [Cites] N Engl J Med. 1977 Dec 15;297(24):1354-5 [917098.001]
  • [Cites] Ann Intern Med. 1979 Oct;91(4):560-2 [484953.001]
  • [Cites] JAMA. 1981 Jan 23-30;245(4):360-3 [7452862.001]
  • [Cites] Am J Gastroenterol. 1983 Mar;78(3):162-3 [6829536.001]
  • [Cites] J Clin Microbiol. 1989 Feb;27(2):305-8 [2915024.001]
  • (PMID = 18474093.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2397406
  •  go-up   go-down


56. Mukenge S, Pulitanò C, Colombo R, Negrini D, Ferla G: Secondary scrotal lymphedema: a novel microsurgical approach. Microsurgery; 2007;27(8):655-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of secondary lymphedema of male genitalia presenting more than 4 years after a radical cystectomy with extended pelvic lymphadenectomy for adenocarcinoma of the bladder.
  • [MeSH-major] Cystectomy / adverse effects. Lymphedema / surgery. Microsurgery / methods. Scrotum / surgery. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Lymphedema.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Lymphedema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17929261.001).
  • [ISSN] 0738-1085
  • [Journal-full-title] Microsurgery
  • [ISO-abbreviation] Microsurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Salinas NR, Lopes CT, Palma PV, Oshima CT, Bueno V: Lung tumor development in the presence of sphingosine 1-phosphate agonist FTY720. Pathol Oncol Res; 2009 Dec;15(4):549-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urethane is a chemical carcinogen which causes lung tumorigenesis in mice with similarities to human adenocarcinoma (AC).
  • The sphingosine 1-phosphate agonist FTY720 administered to mice in doses above 5 mg/kg/day has been able to prevent hepatocellular carcinoma and bladder cancer.
  • We used BALB/c mice in urethane-induced lung cancer model to investigate the effects of a lower dose of FTY720 (1 mg/kg/day).
  • The findings in FTY720 0 Group (nodule multiplicity and area, PCNA expression) were similar to Urethane Group suggesting that the administration of the compound at early time point did not affect lung tumor development.
  • FTY720 (30 days and 90 days) administration decreased CD4 + splenocytes and blood lymphocytes which caused opposite effects in lung tumor development - impairment and improvement respectively.In conclusion, FTY720 in low dose did not provide lung tumor inhibition in mice but its administration 30 days after the chemical carcinogen (Urethane) injection was associated with impaired tumor development.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. ETHYL CARBAMATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Ther Oncol. 2008;7(1):9-15 [18472638.001]
  • [Cites] Toxicol Lett. 2001 Mar 8;119(3):173-81 [11246170.001]
  • [Cites] Transplant Proc. 2005 Jan-Feb;37(1):110-1 [15808563.001]
  • [Cites] Prostate. 1999 Jun 15;40(1):50-5 [10344723.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18514-9 [18000061.001]
  • [Cites] J Natl Cancer Inst. 1983 May;70(5):931-6 [6573537.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):221-31 [16397235.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):1039-48 [15986440.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Sep;134(3):638-43 [17723811.001]
  • [Cites] Exp Lung Res. 2005 Jan-Feb;31(1):57-82 [15765919.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1410-9 [11888913.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):175-82 [10623665.001]
  • [Cites] Am J Pathol. 1989 Apr;134(4):733-9 [2565087.001]
  • [Cites] Bosn J Basic Med Sci. 2007 Aug;7(3):205-11 [17848143.001]
  • [Cites] Virchows Arch. 1995;425(6):583-8 [7697214.001]
  • [Cites] Exp Lung Res. 1998 Jul-Aug;24(4):541-55 [9659582.001]
  • [Cites] Br J Pharmacol. 2003 Apr;138(7):1303-12 [12711631.001]
  • [Cites] Oncogene. 1997 Oct 9;15(15):1833-40 [9362450.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):197-202 [16337739.001]
  • [Cites] J Urol. 2003 Jun;169(6):2372-7 [12771800.001]
  • [Cites] Transplant Proc. 1989 Feb;21(1 Pt 3):3211-4 [2705279.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1924-31 [15026325.001]
  • [Cites] J Pathol. 1990 Dec;162(4):285-94 [1981239.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8458-66 [16322309.001]
  • (PMID = 19214784.001).
  • [ISSN] 1532-2807
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Lysophospholipids; 0 / Proliferating Cell Nuclear Antigen; 0 / Propylene Glycols; 26993-30-6 / sphingosine 1-phosphate; 3IN71E75Z5 / Urethane; EC 3.4.22.- / Caspase 3; G926EC510T / Fingolimod Hydrochloride; NGZ37HRE42 / Sphingosine
  •  go-up   go-down


58. Husmann DA, Rathbun SR: Long-term follow up of enteric bladder augmentations: the risk for malignancy. J Pediatr Urol; 2008 Oct;4(5):381-5; discussion 386
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow up of enteric bladder augmentations: the risk for malignancy.
  • OBJECTIVE: To determine the risk of bladder cancer following enteric bladder augmentation.
  • MATERIALS AND METHODS: Patients followed for care after an enteric bladder augmentation have been entered into a registry; individuals followed for a minimum of 10 years were evaluated.
  • Indications for bladder augmentation were neurogenic bladder in 97, exstrophy in 38 and posterior urethral valves in 18.
  • Two patients with neurogenic bladder developed transitional cell carcinoma; both were heavy smokers (>50 pack per year history).
  • Two patients with a history of posterior urethral valves and renal transplantation developed adenocarcinoma of the enteric augment.
  • Three patients with bladder exstrophy developed multifocal adenocarcinoma of the augmented bladder.
  • Two patients remain alive, 5 and 6 years following radical cystoprostatectomy; five died of cancer-specific causes.
  • CONCLUSIONS: Malignancy following enteric bladder augmentation arose in 4.5% (7/153) of our patients and was associated with coexisting carcinogenic stimuli (prolonged tobacco/chronic immunosuppressive exposure), or alternatively with the inherent risk of malignancy existing with bladder exstrophy.
  • [MeSH-major] Urinary Bladder Diseases / surgery. Urinary Bladder Neoplasms / epidemiology. Urinary Bladder Neoplasms / etiology
  • [MeSH-minor] Child. Follow-Up Studies. Humans. Intestines / transplantation. Risk Assessment. Risk Factors. Time Factors. Urinary Bladder / surgery. Urologic Surgical Procedures / adverse effects


59. Ha YS, Kim YW, Min BD, Lee OJ, Kim YJ, Yun SJ, Lee SC, Kim WJ: Alpha-methylacyl-coenzyme a racemase-expressing urachal adenocarcinoma of the abdominal wall. Korean J Urol; 2010 Jul;51(7):498-500
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl-coenzyme a racemase-expressing urachal adenocarcinoma of the abdominal wall.
  • To demonstrate the origin of the urachal adenocarcinoma is not easy, but it is very important for managing patient care.
  • Computed tomography revealed a well-defined enhancing mass with internal calcification and septation abutting on the dome of the urinary bladder.
  • The clinical diagnosis was urachal cancer, which seemed to invade the urinary bladder.
  • Thus, we performed mass excision and partial resection of the bladder.
  • To our knowledge, this report is the first case of AMACR-expressing urachal adenocarcinoma arising in the abdominal wall.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Sep;18(9):1217-22 [15803184.001]
  • [Cites] Histopathology. 1998 Jan;32(1):20-7 [9522212.001]
  • [Cites] Eur J Surg Oncol. 1997 Apr;23(2):157-60 [9158192.001]
  • [Cites] J Urol. 1986 Jun;135(6):1240-4 [3712579.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1536-42 [17684125.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):228-33 [12673556.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):451-61 [11259707.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1677-82 [10749139.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • (PMID = 20664785.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2907501
  • [Keywords] NOTNLM ; Alpha-methylacyl-CoA racemase / Biological markers / Cystadenocarcinoma, mucinous / Urachus
  •  go-up   go-down


61. Abd El Gawad IA, Moussa HS, Nasr MI, El Gemae EH, Masooud AM, Ibrahim IK, El Hifnawy NM: Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer. J Egypt Natl Canc Inst; 2005 Sep;17(3):193-202
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study of NMP-22, telomerase, and BTA in the detection of bladder cancer.
  • PURPOSE: The diagnostic efficacy of Nuclear Matrix Protein-22 (NMP-22), bladder tumor antigen (BTA TRAK), and telomerase activity was evaluated in urine in a trial to assess their value in the detection of bladder cancer and to compare it to that of routine urine cytology.
  • SUBJECTS AND METHODS: The study included 46 newly diagnosed bladder cancer patients, diagnosed by cystoscopy and histopathological typing, in addition to 20 patients with benign bladder lesions and 20 healthy age and sex matched volunteers as a control group.
  • Fifty percent of the cancer patients (23/46) had proven bilharzial history.
  • Most patients (27/46) had transitional cell carcinoma (TCC), 17/46 had squamous cell carcinoma (SCC), while only 2 patients had adenocarcinoma.
  • For bilharzial cancer bladder respective sensitivities were 69.6%, 95.6%, 100% and 73.9%, while for nonbilharzial cancer bladder the respective sensitivities were 39.1%, 87%, 100% and 87%.
  • CONCLUSION: BTA showed the highest sensitivity in all the studied parameters in the bladder cancer group, bilharzial bladder cancer subgroup, and non bilharzial bladder subgroup, (100%), while the highest specificity was recorded with urine cytology (100%), followed by telomerase (95%), then BTA (92.5%), and lastly NMP- 22 (87.5%).
  • [MeSH-major] Antigens, Neoplasm / urine. Biomarkers, Tumor / urine. Nuclear Proteins / urine. Telomerase / urine. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / urine
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / urine. Adult. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / urine. Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / urine. Female. Humans. Male. Middle Aged. Schistosomiasis haematobia / complications

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799657.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / bladder tumor-associated antigen; 0 / nuclear matrix protein 22; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


62. Abdel Wahab AH, Abo-Zeid HI, El-Husseini MI, Ismail M, El-Khor AM: Role of loss of heterozygosity on chromosomes 8 and 9 in the development and progression of cancer bladder. J Egypt Natl Canc Inst; 2005 Dec;17(4):260-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of loss of heterozygosity on chromosomes 8 and 9 in the development and progression of cancer bladder.
  • Non-random chromosome deletion and LOH at specific chromosomal regions are identified in a number of common human cancers including carcinoma of the bladder, which is considered the most predominant cancer in Egypt due to the prevalence of schistosomiasis.
  • PURPOSE: The main objective of the present study is to clarify the role of chromosomes 8 and 9 in the establishment and/or progression of schistosomiasis-related bladder cancer through detection of LOH of 8 microsatellite markers on both chromosomes.
  • It also aims to compare the LOH pattern of the tested markers between schistosomiasis- associated and non schistosomiasis-associated bladder cancer.
  • MATERIAL AND METHODS: To achieve this purpose, DNA was extracted from the tumor specimens and the corresponding peripheral blood samples of 42 primary bladder cancer patients (schistosomal and non schistosomal).
  • Twenty nine of these were diagnosed as squamous cell type (SCC), 11 were transitional (TCC), and 2 were adenocarcinoma (with different stages and grades).
  • CONCLUSION: Our data indicate that more than one tumor suppressor gene on chromosomes 8 and 9 are involved in high grades of bladder carcinogenesis, one at 8p12 and another at 8q21.1 regions.
  • Also, a region at 8q23-quarter may harbor tumor suppressor gene that involved in metastasis of bladder cancer.
  • Finally, the present study shows no line of demarcation between schistosomiasis-associate and non schistosomiasis-associated bladder cancer in terms of LOH of the tested microsatellite markers on chromosome 8 and 9.
  • This suggests that data obtained from schistosoma-associated bladder cancer can be extrapolated to bladder cancer induced by a schistosomiasis independent mechanism.
  • [MeSH-major] Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 9 / genetics. Loss of Heterozygosity. Schistosomiasis haematobia / complications. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17102820.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


63. Marzocchini R, Malentacchi F, Biagini M, Cirelli D, Luceri C, Caderni G, Raugei G: The expression of low molecular weight protein tyrosine phosphatase is up-regulated in 1,2-dimethylhydrazine-induced colon tumours in rats. Int J Cancer; 2008 Apr 1;122(7):1675-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent studies have assessed the role of low molecular weight protein tyrosine phosphatase (LMW-PTP) in cell transformation and tumour onset and progression, observing a significant increase in the expression of LMW-PTP mRNA and protein in human breast, colon, bladder and kidney tumour samples.
  • Moreover, its enhanced expression is generally prognostic of a more aggressive cancer.
  • Moreover a significant overexpression of LMW-PTP transcript is associated with tumours originating in the proximal (right) part of the colon, confirming an observation already reported for human colon cancer.
  • [MeSH-major] Adenocarcinoma / enzymology. Colonic Neoplasms / enzymology. Protein Tyrosine Phosphatases / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 1,2-DIMETHYLHYDRAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 18058797.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; EC 3.1.3.48 / Protein Tyrosine Phosphatases; IX068S9745 / 1,2-Dimethylhydrazine
  •  go-up   go-down


64. Efthimiou I, Charalampos M, Kazoulis S, Xirakis S, Spiros V, Christoulakis I: Urachal carcinoma presenting with chronic mucusuria: a case report. Cases J; 2008;1(1):288
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urachal adenocarcinoma is a rare tumor and represents 0.17-0.34% of all bladder tumors.
  • After surgical removal of the cyst with a partial cystectomy a mucus adenocarcinoma was diagnosed histologically.The patient after a negative for metastatic disease screen underwent a completion radical cystectomy with pelvic lymph node clearance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2007 Dec 1;110(11):2434-40 [17932892.001]
  • [Cites] Eur Radiol. 2005 Jan;15(1):79-84 [15258826.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2165-72 [1706216.001]
  • [Cites] J Urol. 2003 Apr;169(4):1295-8 [12629346.001]
  • [Cites] Urology. 1985 Sep;26(3):218-21 [4035835.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • [Cites] Urology. 1991 Sep;38(3):223-6 [1887535.001]
  • (PMID = 18973691.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2584088
  •  go-up   go-down


65. Rogers CG, Palapattu GS, Shariat SF, Karakiewicz PI, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, Lerner SP, Schoenberg MP: Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol; 2006 Jun;175(6):2048-53; discussion 2053
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder.
  • PURPOSE: The effect of bladder cancer histological subtypes other than transitional cell carcinoma (nonTCC) on clinical outcomes remains uncertain.
  • We conducted a multi-institutional retrospective study of patients with bladder cancer treated with radical cystectomy to assess the impact of nonTCC histology on bladder cancer specific outcomes.
  • MATERIALS AND METHODS: A total of 955 consecutive patients underwent radical cystectomy with bilateral pelvic lymphadenectomy for bladder cancer at 3 academic institutions.
  • NonTCC histology was present in 67 patients (7%), including squamous cell carcinoma in 26, adenocarcinoma in 13, small cell carcinoma in 10 and other nonTCC subtypes (ie spindle cell carcinoma, carcinosarcoma and undifferentiated carcinoma) in 18.
  • Bladder cancer specific progression and survival were assessed using Kaplan-Meier and multivariate Cox proportional hazards analyses.
  • RESULTS: Bladder cancer specific progression and mortality did not differ significantly between patients with SCC and TCC histologies.
  • Patients with nonTCC and nonSCC bladder cancer were at significantly increased risk for progression and death compared to patients with TCC or SCC (p <0.001).
  • In a multivariate analysis nonTCC and nonSCC histology was associated with an increased risk of bladder cancer progression and death (OR 2.272 and 2.585, respectively, p <0.001), even after adjusting for final pathological stage, lymph node status, lymphovascular invasion and neoadjuvant or adjuvant treatments.
  • CONCLUSIONS: NonTCC and nonSCC histological subtype is an independent predictor of bladder cancer progression and mortality in patients undergoing radical cystectomy for bladder cancer.
  • Patients with bladder TCC and SCC share similar stage specific clinical outcomes.
  • [MeSH-major] Carcinoma, Transitional Cell / mortality. Carcinoma, Transitional Cell / surgery. Cystectomy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / surgery


66. Demir OI, Obuz F, Sağol O, Dicle O: Contribution of diffusion-weighted MRI to the differential diagnosis of hepatic masses. Diagn Interv Radiol; 2007 Jun;13(2):81-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contribution of diffusion-weighted MRI to the differential diagnosis of hepatic masses.
  • Malignant masses included 8 metastases, 4 hepatocellular carcinomas, 4 cholangiocellular carcinomas, and 1 gall bladder adenocarcinoma.
  • [MeSH-major] Liver Diseases / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. Male. Middle Aged. Neoplasm Metastasis. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562512.001).
  • [ISSN] 1305-3825
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


67. Ramirez PT, Slomovitz BM, Soliman PT, Coleman RL, Levenback C: Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience. Gynecol Oncol; 2006 Aug;102(2):252-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total laparoscopic radical hysterectomy and lymphadenectomy: the M. D. Anderson Cancer Center experience.
  • Data collected included age, body mass index, stage, histopathologic subtype, tumor grade, estimated blood loss, perioperative blood transfusions, number and status of lymph nodes obtained, status of surgical margins, length of hospital stay, time to resumption of normal bladder function, intraoperative and postoperative complications, and disease-free interval.
  • Eighteen patients had cervix cancer (5 stage IA2 and 13 stage IB1), and 2 had endometrial cancer (1 stage IB and 1 stage IIIA).
  • Among those with cervix cancer, 12 had adenocarcinoma, 4 squamous cell carcinoma, and 2 adenosquamous carcinoma.
  • The median time to resumption of normal bladder function was 16 days (range, 13-29).
  • [MeSH-minor] Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / surgery. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2007 Feb;104(2):501; author reply 501-3 [17157902.001]
  • (PMID = 16472844.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Kuhar CG, Mesti T, Zakotnik B: Digital ischemic events related to gemcitabine: Report of two cases and a systematic review. Radiol Oncol; 2010 Dec;44(4):257-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 65-year-old man was given the first-line treatment with gemcitabine for the advanced adenocarcinoma of pancreas.
  • A 77-year-old man, ex-smoker, was administered a combination of gemcitabine and cisplatin as the first-line treatment for the locally advanced bladder cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2000 Sep;11(9):1191-4 [11061617.001]
  • [Cites] Mund Kiefer Gesichtschir. 2002 Sep;6(5):331-5 [12448236.001]
  • [Cites] J Rheumatol. 2003 Jun;30(6):1341-3 [12784412.001]
  • [Cites] Rheum Dis Clin North Am. 2003 May;29(2):293-313 [12841296.001]
  • [Cites] Eur J Cancer Care (Engl). 2010 May;19(3):408-9 [19490003.001]
  • [Cites] Clin Ter. 2003 May-Jun;154(3):207-10 [12910811.001]
  • [Cites] Anticancer Drugs. 2003 Nov;14(10):829-32 [14597878.001]
  • [Cites] Neoplasma. 2004;51(5):334-40 [15640936.001]
  • [Cites] J Mal Vasc. 2005 Feb;30(1):53-7 [15924070.001]
  • [Cites] Nephrol Dial Transplant. 2006 Nov;21(11):3038-45 [16968717.001]
  • [Cites] Pain Physician. 2008 Jan;11(1):91-6 [18196175.001]
  • [Cites] Expert Opin Drug Saf. 2008 Nov;7(6):703-16 [18983217.001]
  • (PMID = 22933925.001).
  • [ISSN] 1581-3207
  • [Journal-full-title] Radiology and oncology
  • [ISO-abbreviation] Radiol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Other-IDs] NLM/ PMC3423709
  • [Keywords] NOTNLM ; chemotherapy / digital ischemic events / gemcitabine vascular toxicity
  •  go-up   go-down


69. Hassan KA, Chen G, Kalemkerian GP, Wicha MS, Beer DG: An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res; 2009 Oct 15;15(20):6386-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma.
  • PURPOSE: An embryonic stem cell (ESC) profile correlates with poorly differentiated breast, bladder, and glioma cancers.
  • In this article, we assess the correlation between the ESC profile and clinical variables in lung cancer.
  • EXPERIMENTAL DESIGN: Microarray gene expression analysis was done using Affymetrix Human Genome U133A on 443 samples of human lung adenocarcinoma and 130 samples of squamous cell carcinoma (SCC).
  • RESULTS: Our analysis showed that an increased expression of the ESC gene set and a decreased expression of the Polycomb target gene set identified poorly differentiated lung adenocarcinoma.
  • In addition, this gene expression signature was associated with markers of poor prognosis and worse overall survival in lung adenocarcinoma.
  • CONCLUSIONS: This work suggests that not all poorly differentiated non-small cell lung cancers exhibit a gene expression profile similar to that of ESC, and that other characteristics may play a more important role in the determination of differentiation and survival in SCC of the lung.
  • [MeSH-major] Adenocarcinoma / genetics. Carcinoma, Squamous Cell / genetics. Lung Neoplasms / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2000 Apr;24(4):372-6 [10742100.001]
  • [Cites] Mol Cancer Res. 2009 Mar;7(3):330-8 [19276181.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5 [11707567.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Nat Med. 2002 Aug;8(8):816-24 [12118244.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Cell. 2003 May 30;113(5):643-55 [12787505.001]
  • [Cites] Neuron. 2003 Aug 28;39(5):749-65 [12948443.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Science. 1998 Nov 6;282(5391):1145-7 [9804556.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9328-37 [16230395.001]
  • [Cites] Oncogene. 2006 Mar 16;25(12):1696-708 [16449977.001]
  • [Cites] Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3344-54 [16740756.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7466-72 [16885343.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):111-5 [17122771.001]
  • [Cites] Nature. 2007 Jan 4;445(7123):106-10 [17122772.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1030-7 [17283135.001]
  • [Cites] PLoS One. 2007;2(2):e243 [17327908.001]
  • [Cites] Stem Cells. 2007 Apr;25(4):961-73 [17204602.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4827-33 [17510412.001]
  • [Cites] Cell Death Differ. 2008 Mar;15(3):504-14 [18049477.001]
  • [Cites] Nat Genet. 2008 May;40(5):499-507 [18443585.001]
  • [Cites] Nat Med. 2008 Aug;14(8):822-7 [18641660.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4330-6 [11390661.001]
  • (PMID = 19808871.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K08 CA158425; United States / NCI NIH HHS / CA / P30 CA046592; United States / NCI NIH HHS / CA / P30 CA046592-14; United States / NCI NIH HHS / CA / 5P30 CA46592
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS143924; NLM/ PMC2787085
  •  go-up   go-down


70. Liguori G, Amodeo A, Mucelli FP, Patel H, Marco D, Belgrano E, Trombetta C: Intractable haematuria: long-term results after selective embolization of the internal iliac arteries. BJU Int; 2010 Aug;106(4):500-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Between October 1997 and March 2009, 44 patients (30 men and 14 women; mean age 79 years, range 51-95) with intractable haematuria secondary to advanced pelvic tumour arising from or invading the bladder, underwent internal iliac TAE.
  • Twenty-four patients had transitional carcinoma of the urinary bladder, 12 adenocarcinoma of the prostate, five carcinoma of the uterus, one cancer of the vagina, two carcinoma of the rectum, three carcinoma of the kidney, two simultaneous carcinoma of prostate and bladder, one simultaneous carcinoma of prostate and kidney and one had haemorrhagic cystitis after radiotherapy.
  • [MeSH-major] Embolization, Therapeutic / methods. Hematuria / therapy. Iliac Artery. Pelvic Neoplasms / complications. Urinary Bladder Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20128777.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Maletic V, Cerovic S, Lazic M, Stojanovic M, Stevanovic P: Synchronous and multiple transitional cell carcinoma of the bladder and urachal cyst. Int J Urol; 2008 Jun;15(6):554-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous and multiple transitional cell carcinoma of the bladder and urachal cyst.
  • Among urachal tumors, adenocarcinoma is most frequent, although other histological types can also be found.
  • The synchronous presentation of a urachal transitional cell tumor, along with recurrent superficial bladder tumors has not been reported previously.
  • We are reporting a 49-year-old male patient in whom transitional cell carcinoma of a urachal cyst was found with recurrent, multiple bladder tumors.
  • The diagnosis of urachal cyst tumor was established according to ultrasonography and computed tomography.
  • Most of the bladder tumors were resected transurethrally while open surgical excision of the urachal cyst with en bloc resection of the bladder dome was performed.
  • Recurrent bladder tumors were afterwards treated with Bacillus Calmette Guerin (BCG) instillations.
  • [MeSH-major] Carcinoma, Transitional Cell / complications. Neoplasms, Multiple Primary / complications. Urachal Cyst / complications. Urinary Bladder Neoplasms / complications

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Urachal cyst.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489649.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


72. Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park SH, Park JO, Kim WS, Kang WK, Lee HM, Choi HY, Lim H: Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract. Med Oncol; 2009;26(2):186-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary sites of involvement were the bladder, urethra, urachus, and ureter in 43%, 29%, 19%, and 10% of the patients, respectively.
  • Adenocarcinoma was the most common histological type (67%); squamous cell carcinoma and small cell carcinoma comprised 24 and 10% of the histologic types, respectively.
  • Univariate analysis showed a better median overall survival in patients with adenocarcinoma, compared to non-adenocarcinomas (47 vs. 10 months, P = 0.049).
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Female. Humans. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2007 Feb;69(2):255-9 [17320659.001]
  • [Cites] Eur Urol. 2003 Dec;44(6):672-81 [14644119.001]
  • [Cites] Oncology. 2005;69(5):391-8 [16319510.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1639-45 [15073851.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 5:v118-22 [16807438.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1066-73 [1607913.001]
  • [Cites] Eur Urol. 2000 Jan;37(1):85-9 [10671791.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):297-303 [16342065.001]
  • [Cites] Anticancer Res. 2006 Sep-Oct;26(5B):3865-9 [17094415.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1921-7 [10784633.001]
  • [Cites] J Clin Oncol. 1990 Jun;8(6):1050-5 [2189954.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1172-8 [15700264.001]
  • [Cites] BJU Int. 2005 Mar;95(4):497-502 [15705067.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2876-81 [10561365.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):220-8 [14665607.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4602-8 [16034041.001]
  • [Cites] BJU Int. 2004 Jan;93(2):216-20 [14690486.001]
  • (PMID = 18988001.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


73. Zou P, Povoski SP, Hall NC, Carlton MM, Hinkle GH, Xu RX, Mojzisik CM, Johnson MA, Knopp MV, Martin EW Jr, Sun D: 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results. World J Surg Oncol; 2010 Aug 06;8:65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 124I-HuCC49deltaCH2 for TAG-72 antigen-directed positron emission tomography (PET) imaging of LS174T colon adenocarcinoma tumor implants in xenograft mice: preliminary results.
  • BACKGROUND: 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) is widely used in diagnostic cancer imaging.
  • In contrast, anti-TAG (tumor associated glycoprotein)-72 monoclonal antibodies are highly specific for binding to a variety of adenocarcinomas, including colorectal cancer.
  • The aim of this preliminary study was to evaluate a complimentary determining region (CDR)-grafted humanized CH2-domain-deleted anti-TAG-72 monoclonal antibody (HuCC49deltaCH2), radiolabeled with iodine-124 (124I), as an antigen-directed and cancer-specific targeting agent for PET-based imaging.
  • Subcutaneous tumor implants of LS174T colon adenocarcinoma cells, which express TAG-72 antigen, were grown on athymic Nu/Nu nude mice as the xenograft model.
  • In contrast, approximately 50 minutes after i.v. injection, 18F-FDG failed to demonstrate any increased level of specific localization to a LS174T tumor implant, but showed the propensity toward more nonspecific uptake within the heart, Harderian glands of the bony orbits of the eyes, brown fat of the posterior neck, kidneys, and bladder.
  • CONCLUSIONS: On microPET imaging, 124I-HuCC49deltaCH2 demonstrates an increased level of specific localization to tumor implants of LS174T colon adenocarcinoma cells in the xenograft mouse model on delayed imaging, while 18F-FDG failed to demonstrate this.
  • The antigen-directed and cancer-specific 124I-radiolabled anti-TAG-72 monoclonal antibody conjugate, 124I-HuCC49deltaCH2, holds future potential for use in human clinical trials for preoperative, intraoperative, and postoperative PET-based imaging strategies, including fused-modality PET-based imaging platforms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1992 Dec;216(6):627-32 [1466615.001]
  • [Cites] Cancer Res. 1993 Aug 15;53(16):3776-83 [8339291.001]
  • [Cites] Cancer Biother. 1993 Spring;8(1):95-109 [7529083.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2809-17 [7773931.001]
  • [Cites] Surgery. 1995 Oct;118(4):634-8; discussion 638-9 [7570316.001]
  • [Cites] Am J Surg. 1995 Oct;170(4):315-8 [7573720.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23 Suppl):5957s-5967s [7493377.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):613-20 [8616751.001]
  • [Cites] Dis Colon Rectum. 1996 May;39(5):509-13 [8620799.001]
  • [Cites] Ann Surg Oncol. 1996 May;3(3):310-6 [8726188.001]
  • [Cites] J Nucl Med. 1996 Sep;37(9):1557-62 [8790218.001]
  • [Cites] Semin Nucl Med. 1997 Apr;27(2):94-106 [9144854.001]
  • [Cites] Nucl Med Biol. 1998 May;25(4):317-22 [9639291.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1334-6 [9809561.001]
  • [Cites] Semin Surg Oncol. 1998 Dec;15(4):205-8 [9829371.001]
  • [Cites] Ann Surg Oncol. 1998 Oct-Nov;5(7):590-4 [9831106.001]
  • [Cites] Dis Colon Rectum. 1998 Dec;41(12):1482-7 [9860326.001]
  • [Cites] Cancer Detect Prev. 1990;14(6):651-6 [2257564.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):349-52 [1998477.001]
  • [Cites] Cancer Detect Prev. 1991;15(3):225-9 [2059962.001]
  • [Cites] Ann Surg. 1991 Sep;214(3):321-5; discussion 326-7 [1929612.001]
  • [Cites] Acta Radiol Suppl. 1990;374:123-8 [1966958.001]
  • [Cites] Cancer Biother Radiopharm. 2005 Feb;20(1):16-26 [15778575.001]
  • [Cites] J Nucl Med. 2005 Sep;46(9):1531-6 [16157537.001]
  • [Cites] Bioconjug Chem. 2006 Mar-Apr;17(2):485-92 [16536481.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):1059-66 [16741317.001]
  • [Cites] Int J Clin Oncol. 2006 Aug;11(4):286-96 [16937302.001]
  • [Cites] J Clin Pharmacol. 2007 Feb;47(2):227-37 [17244774.001]
  • [Cites] J Nucl Med. 2007 Apr;48(4):602-7 [17401098.001]
  • [Cites] Semin Nucl Med. 2007 May;37(3):206-22 [17418153.001]
  • [Cites] Clin Transl Oncol. 2007 Aug;9(8):494-505 [17720652.001]
  • [Cites] J Med Invest. 2007 Aug;54(3-4):195-9 [17878667.001]
  • [Cites] J Surg Oncol. 2007 Sep 15;96(4):297-308 [17726663.001]
  • [Cites] Semin Nucl Med. 2007 Nov;37(6):400-19 [17920348.001]
  • [Cites] Nucl Med Biol. 2008 Jan;35(1):143-50 [18158953.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1692-8 [11042562.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2008 Mar;52(1):50-65 [18235421.001]
  • [Cites] Cancer Biother Radiopharm. 1997 Oct;12(5):305-16 [10851481.001]
  • [Cites] Recent Results Cancer Res. 2000;157:281-92 [10857181.001]
  • [Cites] J Nucl Med. 2009 May;50 Suppl 1:106S-21S [19380404.001]
  • [Cites] Eur J Radiol. 2009 Jun;70(3):382-92 [19406595.001]
  • [Cites] Expert Rev Med Devices. 2009 Jul;6(4):347-51 [19572788.001]
  • [Cites] Semin Nucl Med. 2009 Sep;39(5):348-53 [19646559.001]
  • [Cites] Mol Pharm. 2009 Mar-Apr;6(2):428-40 [19718796.001]
  • [Cites] Radiographics. 2007 Oct;27 Suppl 1:S197-213 [18180227.001]
  • [Cites] J Nucl Med. 1976 Jun;17(6):493-502 [1262967.001]
  • [Cites] J Natl Cancer Inst. 1977 May;58(5):1507-12 [857038.001]
  • [Cites] Cancer Res. 1984 Dec;44(12 Pt 1):5744-51 [6498836.001]
  • [Cites] Cancer Res. 1985 Feb;45(2):833-40 [3881173.001]
  • [Cites] Health Phys. 1985 Feb;48(2):141-57 [3882630.001]
  • [Cites] Cancer Res. 1986 Feb;46(2):850-7 [3940648.001]
  • [Cites] NCI Monogr. 1987;(3):63-6 [3821920.001]
  • [Cites] NCI Monogr. 1987;(3):83-7 [3821922.001]
  • [Cites] Phys Med Biol. 2008 Feb 21;53(4):R1-R39 [18263942.001]
  • [Cites] J Nucl Med. 2008 Jun;49(6):938-55 [18483101.001]
  • [Cites] Radiol Clin North Am. 2008 Mar;46(2):225-41, viii [18619378.001]
  • [Cites] Handb Exp Pharmacol. 2008;(185 Pt 1):109-32 [18626801.001]
  • [Cites] BMC Med Imaging. 2008;8:16 [18925932.001]
  • [Cites] World J Surg Oncol. 2009;7:11 [19173715.001]
  • [Cites] Curr Pharm Des. 2009;15(9):957-65 [19275660.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2009 Apr;53(2):158-66 [19293764.001]
  • [Cites] Q J Nucl Med Mol Imaging. 2009 Apr;53(2):224-44 [19293770.001]
  • [Cites] Appl Radiat Isot. 2001 May;54(5):749-52 [11258523.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):298-301 [11373109.001]
  • [Cites] World J Surg. 2001 Dec;25(12):1495-8; discussion 1499 [11775180.001]
  • [Cites] Ann Surg Oncol. 2004 Feb;11(2):197-202 [14761924.001]
  • [Cites] J Med Invest. 2004 Feb;51(1-2):14-9 [15000251.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S125-34 [15085295.001]
  • [Cites] JAMA. 1967 Jun 19;200(12):1036-40 [5337789.001]
  • [Cites] Radiology. 1975 Jan;114(1):89-98 [1208874.001]
  • [Cites] In Vitro. 1976 Mar;12(3):180-91 [1262041.001]
  • [Cites] Cancer Res. 1987 Aug 1;47(15):4218-24 [3607761.001]
  • [Cites] Dis Colon Rectum. 1987 Oct;30(10):761-4 [3652889.001]
  • [Cites] Cancer Res. 1988 Aug 15;48(16):4597-603 [3396011.001]
  • [Cites] Int J Cancer. 1988 Sep 15;42(3):352-8 [3417363.001]
  • [Cites] Cancer Res. 1988 Dec 1;48(23):6811-8 [3180090.001]
  • [Cites] Am J Surg. 1988 Nov;156(5):386-92 [3189709.001]
  • [Cites] Surg Gynecol Obstet. 1989 Jul;169(1):35-40 [2740968.001]
  • [Cites] J Surg Res. 1989 Sep;47(3):227-34 [2770279.001]
  • [Cites] Surgery. 1992 Oct;112(4):624-9; discussion 629-30 [1411932.001]
  • [Cites] Int J Cancer. 1993 Jan 2;53(1):97-103 [8416208.001]
  • (PMID = 20691066.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120023
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / B72.3 antibody; 0 / Glycoproteins; 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 0 / tumor-associated antigen 72; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2924340
  •  go-up   go-down


74. Newman RG, Mehler SJ, Kitchell BE, Beal MW: Use of a balloon-expandable metallic stent to relieve malignant urethral obstruction in a cat. J Am Vet Med Assoc; 2009 Jan 15;234(2):236-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE DESCRIPTION: A 19-year-old neutered male domestic shorthair cat was evaluated because of signs of urinary tract obstruction.
  • CLINICAL FINDINGS: Physical examination findings were consistent with urethral obstruction, and a mass could be palpated in the region of the bladder neck.
  • Abdominal ultrasonography and thoracic radiography revealed a mass in the trigone of the urinary bladder and a solitary mass in the left caudal lung lobe.
  • Cytologic examination of the urine sediment, samples obtained by means of traumatic urethral catheterization, and fine-needle aspirates of the bladder mass did not result in a diagnosis.
  • After stent placement, the cat had signs of urinary incontinence and detrusor atony, both of which resolved with medical treatment.
  • Histologic examination of necropsy samples revealed grade III urothelial carcinoma and papillary pulmonary adenocarcinoma.
  • CLINICAL RELEVANCE: Findings suggested that stent placement may be a viable palliative treatment in cats with malignant urinary obstruction.
  • [MeSH-minor] Adenocarcinoma, Papillary / secondary. Adenocarcinoma, Papillary / veterinary. Animals. Cats. Fatal Outcome. Lung Neoplasms / secondary. Lung Neoplasms / veterinary. Male. Palliative Care. Treatment Outcome. Urologic Neoplasms / complications. Urologic Neoplasms / surgery. Urologic Neoplasms / veterinary

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19210243.001).
  • [ISSN] 0003-1488
  • [Journal-full-title] Journal of the American Veterinary Medical Association
  • [ISO-abbreviation] J. Am. Vet. Med. Assoc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Castillo OA, Aranguibel JC, Sánchez-Salas R, Foneron A, Vitagliano G, Díaz M, Fajardo M: [Partial cystectomy. Our series]. Arch Esp Urol; 2007 Nov;60(9):1.111-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Partial cystectomy is a recognized bladder sparing surgical technique.
  • Partial cystectomy was indicated for the treatment of a foreign body, endometriosis, urachal adenocarcinoma, trancisional cell carcinoma, acquired lesions of urachus and extravesical tumor.
  • RESULTS: Nine patients with bladder lesions were laparoscopically operated for partial cystectomy.
  • It is a useful technique for both benign and malignant bladder disease.
  • [MeSH-major] Cystectomy / methods. Urinary Bladder Diseases / surgery

  • MedlinePlus Health Information. consumer health - Bladder Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077866.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


76. Koda S, Mita K, Shigeta M, Usui T: Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery. Jpn J Clin Oncol; 2007 Apr;37(4):296-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery.
  • OBJECTIVE: The aim of this study was to clarify whether intravesical recurrence of upper urinary tract cancer after treatment is related to the mode of surgery or other oncological factors.
  • METHODS: We evaluated 106 patients (mean age 70.4 years; mean follow-up 24.0 months) who underwent surgery for the upper urinary tract cancer at Hiroshima University and its affiliated hospitals between January 1995 and August 2005.
  • Twenty-eight (26%) of the 106 patients had a pre-operative history of bladder cancer.
  • We identified the risk factors predicting intravesical recurrence of upper urinary tract cancer according to the type of previous surgery using the Kaplan-Meier method, log-rank test, and univariate and multivariate analysis using the Cox proportional hazards model.
  • RESULTS: Thirty-one (29%) of the 106 patients developed bladder tumors post-operatively.
  • Multivariate analysis identified only a history of pre-operative bladder tumor (HR = 3.25, P = 0.003) as a predictor of post-operative intravesical recurrence.
  • CONCLUSIONS: Intravesical recurrence after surgery for upper urinary tract cancer is not related to the mode of surgery (i.e. laparoscopy-assisted or open surgery) employed.
  • The only risk factor for intravesical recurrence is a history of bladder cancer.
  • [MeSH-major] Urinary Bladder Neoplasms / pathology. Urologic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Chemotherapy, Adjuvant. Follow-Up Studies. Humans. Kidney Neoplasms / surgery. Kidney Pelvis. Laparoscopy. Neoplasm Recurrence, Local. Nephrectomy / methods. Risk Factors. Ureter / surgery. Ureteral Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17513309.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


77. Hosseini SY, Danesh AK, Parvin M, Basiri A, Javadzadeh T, Safarinejad MR, Nahabedian A: Incidental prostatic adenocarcinoma in patients with PSA less than 4 ng/mL undergoing radical cystoprostatectomy for bladder cancer in Iranian men. Int Braz J Urol; 2007 Mar-Apr;33(2):167-73; discussion 173-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental prostatic adenocarcinoma in patients with PSA less than 4 ng/mL undergoing radical cystoprostatectomy for bladder cancer in Iranian men.
  • OBJECTIVE: To assess the incidence of prostate adenocarcinoma in patients undergoing radical cystoprostatectomy due to bladder cancer in Iranian men.
  • MATERIALS AND METHODS: Fifty cystoprostatectomy specimens removed due to bladder malignancy (2004-2005) at two referral centers (Shaheed Modarress and Shaheed Labbafinejad Hospitals, Tehran, Iran) were examined for the coincidental finding of prostate cancer (PCa).
  • RESULTS: Incidentally detected cancer was found in 7 (14%) of cystoprostatectomy specimens.
  • HGPIN was present in 1 (14.3%) of the cystoprostatectomies with incidentally detected prostate cancer.
  • None of cystoprostatectomies without prostate cancer had HGPIN.
  • CONCLUSION: We conclude that incidentally detected prostate cancer in Iran is lower than the rates reported in other countries.
  • Further studies are warranted for better declaration of variability of prostate cancer between different ethnic groups.
  • [MeSH-major] Adenocarcinoma / diagnosis. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery


78. Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients. Int Semin Surg Oncol; 2007 Sep 20;4:23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative bi-fractionated accelerated radiation therapy for combined treatment of locally advanced rectal cancer in a consectutive series of unselected patients.
  • BACKGROUND: although preoperative RT (Radiation Therapy) is becoming the preferred approach for combined treatment of locally advanced rectal adenocarcinoma, no regimen can be now considered as a standard.
  • METHODS: patients were screened following these eligibility criteria: histology-proven adenocarcinoma of the rectum; distal tumour extent at 12 cm or less from the anal verge; clinical stage T3-4/anyN, or anyT/N1-2; ECOG Performance Status 0-2.
  • Long-term complications included 1 case of radiation enteritis requiring surgery, 2 cases of anastomotic stricture and 3 cases of bladder incontinence.
  • CONCLUSION: bifractionated accelerated RT administered in the preoperative setting to patients bearing locally advanced rectal cancer is reliable and safe, as its immediate and late toxicity (mainly infectious) is acceptably low and long-term survivals are achievable.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1990 Feb;211(2):187-95 [2405793.001]
  • [Cites] Am J Surg. 1994 Jan;167(1):90-4; discussion 94-5 [8311145.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):157-67 [9488510.001]
  • [Cites] J Natl Cancer Inst. 2000 Mar 1;92(5):388-96 [10699069.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] Ann Surg. 2001 Nov;234(5):633-40 [11685026.001]
  • [Cites] Lancet. 2000 Jul 8;356(9224):93-6 [10963244.001]
  • [Cites] Ann Surg. 1994 Nov;220(5):676-82 [7979617.001]
  • [Cites] Br J Radiol. 1989 Aug;62(740):679-94 [2670032.001]
  • [Cites] Strahlenther Onkol. 2002 May;178(5):259-62 [12082685.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):964-8 [8813788.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):67-73 [7826163.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):757-61 [1643999.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):593-8 [6735750.001]
  • [Cites] N Engl J Med. 1997 Apr 3;336(14):980-7 [9091798.001]
  • [Cites] N Engl J Med. 1994 Aug 25;331(8):502-7 [8041415.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2396 [10561302.001]
  • [Cites] Strahlenther Onkol. 2004 Jan;180(1):5-14 [14704839.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):387-92 [1587760.001]
  • [Cites] Lancet. 2001 Oct 20;358(9290):1291-304 [11684209.001]
  • [Cites] Clin Radiol. 1971 Apr;22(2):145-55 [5575251.001]
  • (PMID = 17883838.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2063497
  •  go-up   go-down


79. Chalasani V, Chin JL, Izawa JI: Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer. Can Urol Assoc J; 2009 Dec;3(6 Suppl 4):S193-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer.
  • Bladder cancer can be classified histologically as urothelial or non-urothelial.
  • Urothelial cancer has a propensity for divergent differentiation, which has increasingly been recognized in recent years due to heightened awareness and improved immunohistochemistry techniques.
  • Furthermore, the recent World Health Organization classification of urothelial cancers improved clarity on this issue, with its listing of 13 histologic variants of urothelial cancer.
  • The divergent differentiation patterns include, amongst others, squamous, glandular, micropapillary, nested, lymphepithelioma-like, plasmacytoid and sarcomatoid variants of urothelial cancer.
  • Genetic-based studies have indicated that the histologic variants of urothelial cancer arise from a common clonal precursor.
  • Mostly, the current evidence suggests that urothelial cancer with divergent differentiation has a worse prognosis when compared with pure urothelial cancer.
  • This article will review the current literature on variant histologies of urothelial cancer, and well as new developments in pure squamous cell carcinoma, small cell carcinoma and adenocarcinoma of the bladder.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(3):511-7 [1612951.001]
  • [Cites] Ann Oncol. 1991 Feb;2(2):137-40 [2054316.001]
  • [Cites] Ann Diagn Pathol. 2005 Feb;9(1):1-5 [15692943.001]
  • [Cites] Int J Clin Oncol. 2005 Feb;10(1):20-5 [15729596.001]
  • [Cites] Urology. 2005 Nov;66(5):1122-6 [16286151.001]
  • [Cites] Urol Oncol. 2006 Jan-Feb;24(1):13-20 [16414487.001]
  • [Cites] J Urol. 2006 Mar;175(3 Pt 1):881-5 [16469571.001]
  • [Cites] Urology. 2006 Mar;67(3 Suppl 1):11-7; discussion 17-8 [16530068.001]
  • [Cites] Eur Urol. 2006 Nov;50(5):1111-4 [16626859.001]
  • [Cites] J Urol. 2006 Jun;175(6):2048-53; discussion 2053 [16697800.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):721-8 [16826584.001]
  • [Cites] J Clin Pathol. 2007 Mar;60(3):332-5 [16882698.001]
  • [Cites] World J Urol. 2006 Nov;24(5):531-42 [17115230.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Dec;6(12):1715-21 [17181485.001]
  • [Cites] Urol Oncol. 2007 Jan-Feb;25(1):38-45 [17208137.001]
  • [Cites] J Pathol. 2007 Mar;211(4):420-30 [17236170.001]
  • [Cites] Urology. 2007 Jan;69(1 Suppl):93-104 [17280911.001]
  • [Cites] Hum Pathol. 2007 May;38(5):741-6 [17306328.001]
  • [Cites] Int Urol Nephrol. 2007;39(3):803-7 [17333523.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):828-34 [17541442.001]
  • [Cites] Cancer. 2007 Jul 1;110(1):62-7 [17542024.001]
  • [Cites] Int Braz J Urol. 2007 May-Jun;33(3):339-45; discussion 346 [17626650.001]
  • [Cites] Urology. 2007 Jul;70(1):69-74 [17656211.001]
  • [Cites] Curr Opin Urol. 2007 Sep;17(5):363-8 [17762632.001]
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):733-9 [17951193.001]
  • [Cites] Urol Oncol. 2009 Jan-Feb;27(1):3-7 [18367107.001]
  • [Cites] World J Urol. 2009 Feb;27(1):101-6 [18607595.001]
  • [Cites] Hum Pathol. 2009 Jan;40(1):108-16 [18789486.001]
  • [Cites] Urology. 2009 Jan;73(1):147-52 [18848348.001]
  • [Cites] Mod Pathol. 2009 Jan;22(1):113-8 [18997737.001]
  • [Cites] BJU Int. 2008 Nov;102(9 Pt B):1216-20 [19035884.001]
  • [Cites] Int J Clin Exp Pathol. 2009;2(2):194-9 [19079656.001]
  • [Cites] Urology. 2009 Apr;73(4):822-7 [19193403.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):764-9 [17614317.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 Jul;7(7):1015-26 [17627461.001]
  • [Cites] J Urol. 2007 Dec;178(6):2302-6; discussion 2307 [17936803.001]
  • [Cites] Am J Surg Pathol. 2007 Dec;31(12):1777-87 [18043032.001]
  • [Cites] Pathology. 2008 Apr;40(3):310-1 [18428056.001]
  • [Cites] J Urol. 2008 Nov;180(5):1923-7 [18801525.001]
  • [Cites] Can Urol Assoc J. 2008 Oct;2(5):540-2 [18953454.001]
  • [Cites] BJU Int. 2009 Mar;103(6):747-52 [19076139.001]
  • [Cites] Histopathology. 2009 Jun;54(7):885-900 [19178589.001]
  • [Cites] J Postgrad Med. 2009 Jan-Mar;55(1):33-4 [19242076.001]
  • [Cites] J Clin Pathol. 1989 Mar;42(3):250-3 [2703540.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1590-6 [3171626.001]
  • [Cites] Am J Surg Pathol. 1994 Dec;18(12):1224-32 [7977945.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):316-29 [8001003.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):466-73 [8172321.001]
  • [Cites] Mod Pathol. 1996 Oct;9(10):989-94 [8902836.001]
  • [Cites] J Urol. 1997 Aug;158(2):393-9 [9224310.001]
  • [Cites] J Urol. 1998 May;159(5):1497-503 [9554341.001]
  • [Cites] J Urol. 1998 May;159(5):1624-9 [9554367.001]
  • [Cites] Br J Urol. 1998 Aug;82(2):206-12 [9722755.001]
  • [Cites] J Urol. 1999 Jun;161(6):1798-802 [10332438.001]
  • [Cites] Lancet. 1999 Aug 14;354(9178):533-40 [10470696.001]
  • [Cites] Scand J Urol Nephrol. 2001 Apr;35(2):102-5 [11411650.001]
  • [Cites] Virchows Arch. 2001 Jun;438(6):552-7 [11469686.001]
  • [Cites] Urology. 2002 Feb;59(2):232-8; discussion 238-9 [11834392.001]
  • [Cites] Int Urol Nephrol. 2001;33(4):631-3 [12452615.001]
  • [Cites] Histopathology. 2004 Jul;45(1):55-64 [15228444.001]
  • [Cites] J Urol. 2004 Aug;172(2):481-4 [15247709.001]
  • [Cites] Urology. 2004 Oct;64(4):744-8 [15491713.001]
  • (PMID = 20019984.001).
  • [ISSN] 1920-1214
  • [Journal-full-title] Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • [ISO-abbreviation] Can Urol Assoc J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2792446
  •  go-up   go-down


80. Adley BP, Maxwell K, Dalton DP, Yang XJ: Urothelial-type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma. Int Braz J Urol; 2006 Nov-Dec;32(6):681-7; discussion 687-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urothelial-type adenocarcinoma of the prostate mimicking metastatic colorectal adenocarcinoma.
  • Adenocarcinoma arising in urinary bladder or prostatic urethra is uncommon.
  • Here we report the fifth case of a primary urothelial-type adenocarcinoma arising in the prostate which showed enteric differentiation.
  • The patient was a 55 year-old male whose prostatic needle core biopsy showed a high grade adenocarcinoma which was initially thought to be metastatic colon cancer.
  • Subsequent prostatectomy revealed a high grade adenocarcinoma which was positive for cytokeratins 7 and 20, carcinoembryonic antigen, CDX2, and high molecular weight cytokeratin, and negative for prostate specific antigen, prostate specific acid phosphatase and AMACR.
  • A diagnosis of urothelial-type adenocarcinoma of the prostate was rendered.
  • We review the literature regarding this entity, and discuss the differential diagnosis, emphasizing utility of immunohistochemistry in making the diagnosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Colorectal Neoplasms / pathology. Prostatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Necrosis. Prostatectomy. Urothelium

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17201946.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


81. Ryu HS, Park YL, Park SJ, Lee JH, Cho SB, Lee WS, Chung IJ, Kim KK, Lee KH, Kweon SS, Joo YE: KITENIN is associated with tumor progression in human gastric cancer. Anticancer Res; 2010 Sep;30(9):3479-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] KITENIN is associated with tumor progression in human gastric cancer.
  • BACKGROUND: KAI1 COOH-terminal interacting tetraspanin (KITENIN) promotes tumor cell migration, invasion and metastasis in colon, bladder, head and neck cancer.
  • The aims of current study were to evaluate whether KITENIN affects tumor cell behavior in human gastric cancer cell line and to document the expression of KITENIN in a well-defined series of gastric tumors, including complete long-term follow-up, with special reference to patient prognosis.
  • MATERIALS AND METHODS: To evaluate the impact of KITENIN knockdown on behavior of a human gastric cancer cell line, AGS, migration, invasion and proliferation assays using small-interfering RNA were performed.
  • The expression of KITENIN and AP-1 target genes by RT-PCR and Western blotting or immunohistochemistry was also investigated in human gastric cancer tissues.
  • KITENIN expression was significantly increased in human cancer tissues at RNA and protein levels.
  • Expression of MMP-1, MMP-3, COX-2 and CD44 were significantly increased in human gastric cancer tissues.
  • Immunostaining of KITENIN was predominantly identified in the cytoplasm of cancer cells.
  • DISCUSSION: These results indicate that KITENIN plays an important role in human gastric cancer progression by AP-1 activation.
  • [MeSH-major] Adenocarcinoma / pathology. Biomarkers, Tumor / analysis. Carrier Proteins / metabolism. Membrane Proteins / metabolism. Stomach Neoplasms / pathology


82. Marques ML, D'Alessandro GS, Chade DC, Lanzoni VP, Saiovici S, Almeida CJ: Primary mucinous adenocarcinoma of the bladder with signet-ring cells: case report. Sao Paulo Med J; 2007 Sep 6;125(5):297-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary mucinous adenocarcinoma of the bladder with signet-ring cells: case report.
  • CONTEXT: Primary adenocarcinomas of the bladder are uncommon and usually occur by contiguity with or hematogenic dissemination of other adenocarcinomas such as colorectal, prostate and gynecological tract carcinomas.
  • Mucinous and signet-ring cell histological patterns are even rarer and it is often difficult to morphologically distinguish them from metastatic colorectal adenocarcinoma.
  • CASE REPORT: We present and discuss a rare case of primary mucinous adenocarcinoma of the bladder with signet-ring cells in a 57-year-old male patient.
  • Other primary sites for the tumor had been excluded and, in the absence of digestive tract tumor and for confirmation that it was a primary bladder tumor, an immunohistochemistry study was performed.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Signet Ring Cell / diagnosis. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Humans. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Mucin-2. Mucins / analysis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18094900.001).
  • [ISSN] 1516-3180
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


83. Lai CR, Hsu CY, Tsay SH, Li AF: Clinical significance of atypical glandular cells by the 2001 Bethesda System in cytohistologic correlation. Acta Cytol; 2008 Sep-Oct;52(5):563-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Women with AGC, favor neoplasia, were more likely to have significant pathology than those with AGC, not otherwise specified, 74% vs. 33% (p = 0.002).
  • Some characteristic background cytologic findings were also noticed in most cases of endometrial, fallopian tube and endocervical adenocarcinoma.
  • CONCLUSION: A diagnosis of AGC is more clinically significant by the 2001 Bethesda System, especially the "AGC, favor neoplastic" category.
  • [MeSH-major] Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Ovarian Neoplasms / pathology. Precancerous Conditions / pathology. Rectal Neoplasms / pathology. Urinary Bladder Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Female. Humans. Middle Aged. Papanicolaou Test. Retrospective Studies. Sarcoma, Endometrial Stromal / pathology. Vaginal Smears / methods


84. Kobayashi S, Tsukamoto T, Tohsaka A, Tohma T: [A case of adenocarcinoma of the urinary bladder arising 45 years after ileal replacement of ureter for tuberculous ureteral stricture]. Hinyokika Kiyo; 2008 Mar;54(3):235-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adenocarcinoma of the urinary bladder arising 45 years after ileal replacement of ureter for tuberculous ureteral stricture].
  • We report a case of adenocarcinoma arising in the urinary bladder 45 years after ileal replacement of ureter for tuberculous ureteral stricture.
  • Cystoscopic examination demonstrated a broadbased non-papillary tumor on the left posterior wall of the bladder and a papillary tumor at the anastomotic site between the bladder and ileal segment.
  • The histopathological examination demonstrated well differentiated adenocarcinoma of the bladder and ileal ureter.
  • Intestinal metaplasia widely infiltrated into the bladder epithelium around the anastomotic site.
  • [MeSH-major] Adenocarcinoma / etiology. Tuberculosis, Urogenital / surgery. Ureteral Obstruction / surgery. Urinary Bladder Neoplasms / etiology. Urinary Diversion

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18411782.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. Ketata S, Boulaire JL, Al-Ahdab N, Bargain A, Damamme A: Spontaneous intraperitoneal perforation of the bladder: a late complication of radiation therapy for prostate cancer. Clin Genitourin Cancer; 2007 Mar;5(4):287-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous intraperitoneal perforation of the bladder: a late complication of radiation therapy for prostate cancer.
  • The spontaneous intraperitoneal rupture of the urinary bladder is an extremely rare and life-threatening event.
  • Often, there are difficulties in establishing the diagnosis.
  • A patient with spontaneous perforation of the urinary bladder, 17 years after successful treatment of an adenocarcinoma of the prostate by pelvic radiation therapy, is reported.
  • Aspects of etiology, clinical presentation, diagnosis, and management are described.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Prostatic Neoplasms / radiotherapy. Urinary Bladder Diseases / diagnosis. Urinary Bladder Diseases / etiology
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Rupture, Spontaneous / diagnosis. Rupture, Spontaneous / etiology. Rupture, Spontaneous / surgery. Tomography, X-Ray Computed


86. Kim YJ, Im SA, Kim HG, Oh SY, Lee KW, Choi IS, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Kim SW, Heo DS, Yoon YB, Bang YJ: A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol; 2008 Jan;19(1):99-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
  • BACKGROUND: Optimal chemotherapy for advanced biliary tract cancer (BTC) is yet to be defined.
  • RESULTS: Fifty-one BTC patients (metastatic:relapsed = 37:14, Gall-bladder:intrahepatic bile ducts:extrahepatic bile ducts = 16:25:10) were enrolled from January 2005 to December 2006.

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846018.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin; UA8SE1325T / gimeracil
  •  go-up   go-down


87. Berberian JP, Goeman L, Allory Y, Abbou CC, Salomon L: Adenocarcinoma of ileal neobladder 20 years after cystectomy. Urology; 2006 Dec;68(6):1343.e9-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of ileal neobladder 20 years after cystectomy.
  • We present the case of a 67-year-old man with adenocarcinoma of the ileal neobladder 20 years after radical cystoprostatectomy for Stage pT2 transitional bladder cell cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Cystectomy / methods. Ileal Neoplasms / pathology. Urinary Diversion
  • [MeSH-minor] Aged. Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Cystoscopy. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Reoperation. Time Factors. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17141834.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Ghosh L, Dahut W, Kakar S, Posadas EM, Torres CG, Cancel-Santiago R, Ghosh BC: Management of patients with metastatic cancer of unknown primary. Curr Probl Surg; 2005 Jan;42(1):12-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of patients with metastatic cancer of unknown primary.
  • [MeSH-major] Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / therapy. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Biomarkers, Tumor / analysis. Brain Neoplasms / secondary. Breast Neoplasms / diagnosis. Breast Neoplasms / secondary. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Cell Differentiation. Cytogenetic Analysis. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / pathology. Humans. Immunohistochemistry. Keratins / metabolism. Liver Neoplasms / diagnosis. Lymphatic Metastasis. Magnetic Resonance Imaging. Mesothelioma / diagnosis. Mesothelioma / metabolism. Peritoneal Neoplasms / pathology. Positron-Emission Tomography. Prognosis. Rhabdomyosarcoma / pathology. Tomography, X-Ray Computed. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711508.001).
  • [ISSN] 0011-3840
  • [Journal-full-title] Current problems in surgery
  • [ISO-abbreviation] Curr Probl Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  • [Number-of-references] 147
  •  go-up   go-down


89. Nakano M, Uno H, Gotoh T, Kubota Y, Ishihara S, Deguchi T, Hayashi S, Matsuo M, Tanaka O, Hoshi H: Migration of prostate brachytherapy seeds to the vertebral venous plexus. Brachytherapy; 2006 Apr-Jun;5(2):127-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three months after brachytherapy, routine followup kidney-urinary bladder (KUB) radiography showed two seeds that had migrated to the pelvic area and were overlapped by sacral bone.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / adverse effects. Prostatic Neoplasms / radiotherapy. Spine

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644468.001).
  • [ISSN] 1538-4721
  • [Journal-full-title] Brachytherapy
  • [ISO-abbreviation] Brachytherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


90. Nasiri S, Gafuri A, Karamnejad M, Farshidfar F: Four port-site recurrences of gall bladder cancer after laparoscopic cholecystectomy. ANZ J Surg; 2009 Jan-Feb;79(1-2):75-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four port-site recurrences of gall bladder cancer after laparoscopic cholecystectomy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Cholecystectomy, Laparoscopic. Gallbladder Neoplasms / pathology. Gallbladder Neoplasms / surgery. Neoplasm Recurrence, Local / pathology. Postoperative Complications / pathology


91. Luo JH, Xie D, Chen W, Dai YP, Li XF, Tao Y, Zheng KL: [Correlation of clusterin expression to prognosis of bladder carcinoma]. Ai Zheng; 2005 Jun;24(6):743-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of clusterin expression to prognosis of bladder carcinoma].
  • BACKGROUND & OBJECTIVE: Clinically, molecular prognostic markers for bladder carcinoma are still rare.
  • Recently, up-regulation of clusterin protein has been suggested to relate with development and prognosis of several human cancers, but its relation with bladder cancer is unclear.
  • This study was to analyze correlation of expression of clusterin protein to clinicopathologic parameters and prognosis of bladder cancer with tissue chip.
  • METHODS: A tissue microarray containing 81 cases of bladder carcinoma was constructed.
  • RESULTS: Of the 81 cases of bladder cancer, 69 were detectable by immunohistochemistry, 32 (46.4%) of which showed overexpression of clusterin protein.
  • Expression of clusterin was negatively correlated with prognosis of bladder cancer patients (log-rank=5.88, P=0.015); the recurrence-free survival time of patients with overexpression of clusterin was shorter than that of patients with normal expression of clusterin (37.3 months vs. 48.8 months).
  • CONCLUSION: The overexpression of clusterin might be a molecular prognostic marker of bladder cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Transitional Cell / metabolism. Clusterin / metabolism. Urinary Bladder Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Prognosis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946493.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Clusterin
  •  go-up   go-down


92. Spiess PE, Correa JJ: Robotic assisted laparoscopic partial cystectomy and urachal resection for urachal adenocarcinoma. Int Braz J Urol; 2009 Sep-Oct;35(5):609
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic assisted laparoscopic partial cystectomy and urachal resection for urachal adenocarcinoma.
  • A case of robotic assisted partial cystectomy and urachal resection for urachal adenocarcinoma is presented.
  • METHODS: A 55 years old African American male presented with hematuria and mucosuria, cystoscopy demonstrated a tumor involving the dome of the bladder.
  • Transurethral biopsy confirmed a urachal adenocarcinoma.
  • Preoperative abdominal/pelvic CT imaging revealed an enhancing mass extending from the inferior level of the umbilicus to the dome of the bladder.
  • The robotic assisted laparoscopic dissection was started at the level of the umbilicus, dissecting lateral to the right and left medial umbilical ligaments up until the dome of the bladder.
  • A simultaneous cystoscopy with transillumination to define the bladder boundaries of this mass, with robotic assisted laparoscopic opening of the bladder, with the entire mass (including bladder component) excised and sent for frozen pathology for margin evaluation.
  • After specimen extraction, the bladder was closed in two layers.
  • RESULTS: Final pathology reported a pT2N0Mx adenocarcinoma with negative margins and negative pelvic lymph nodes.
  • A cystogram perfomed on postoperative day 7 revealed a good bladder capacity (350 cc) and no leakage was identified.
  • CONCLUSIONS: Robotic assisted partial cystectomy and urachal resection for urachal adenocarcinoma of the bladder is feasible even in challenging cases.
  • [MeSH-major] Adenocarcinoma / surgery. Urachus / surgery. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Urachal adenocarcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19860941.001).
  • [ISSN] 1677-6119
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Video-Audio Media
  • [Publication-country] Brazil
  •  go-up   go-down


93. Grey BR, Clarke L, Maddineni SB, Hunt R, Brough RJ: Adenocarcinoma of the caecum metastatic to the bladder: an unusual cause of haematuria. BMC Urol; 2006;6:29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the caecum metastatic to the bladder: an unusual cause of haematuria.
  • BACKGROUND: Primary malignancies of colorectal origin can metastasise to the bladder.
  • Subsequently, a metastatic lesion to the bladder was demonstrated and successfully excised by partial cystectomy.
  • CONCLUSION: In order that optimal therapeutic options can be determined, it is important for clinicians to distinguish between primary disease of the bladder and other causes of haematuria.
  • Various immunohistochemical techniques attempt to differentiate primary adenocarcinoma of the bladder from secondary colorectal adenocarcinoma.
  • Suspicion of metastatic disease must be raised when histologically unusual bladder tumours are identified.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / secondary. Cecal Neoplasms / complications. Cecal Neoplasms / diagnosis. Hematuria / diagnosis. Hematuria / etiology. Urinary Bladder Neoplasms / complications. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Female. Humans. Rare Diseases / diagnosis. Rare Diseases / etiology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1380-7 [11684954.001]
  • [Cites] J Urol. 2001 Mar;165(3):905 [11176504.001]
  • [Cites] Arch Pathol Lab Med. 2002 Sep;126(9):1057-63 [12204054.001]
  • [Cites] Arch Esp Urol. 2002 Dec;55(10):1277-9 [12611231.001]
  • [Cites] Clin Colorectal Cancer. 2003 May;3(1):54-7 [12777193.001]
  • [Cites] Onkologie. 2003 Jun;26(3):249-51 [12845209.001]
  • [Cites] Br J Urol. 1987 Feb;59(2):193-4 [3828721.001]
  • [Cites] Am J Surg Pathol. 1990 Sep;14(9):877-80 [2389818.001]
  • [Cites] Urol Radiol. 1992;13(3):187-9 [1539411.001]
  • [Cites] Am J Surg Pathol. 1993 Feb;17(2):171-8 [8422112.001]
  • [Cites] Int Urol Nephrol. 1995;27(3):297-300 [7591593.001]
  • [Cites] Acta Oncol. 1997;36(2):219-20 [9140441.001]
  • [Cites] Rozhl Chir. 1997 Dec;76(12):619-21 [9511409.001]
  • [Cites] J Urol. 1955 Oct;74(4):498-521 [13264313.001]
  • [Cites] J Urol. 1956 Jun;75(6):965-72 [13320594.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1217-22 [15803184.001]
  • [Cites] Histopathology. 2000 Jan;36(1):32-40 [10632749.001]
  • [Cites] Urology. 2002 Jan;59(1):138 [11796308.001]
  • (PMID = 17040576.001).
  • [ISSN] 1471-2490
  • [Journal-full-title] BMC urology
  • [ISO-abbreviation] BMC Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1624844
  •  go-up   go-down


94. Domanowska E, Jozwicki W, Domaniewski J, Golda R, Skok Z, Wiśniewska H, Sujkowska R, Wolski Z, Jozwicka G: Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize. Hum Pathol; 2007 May;38(5):741-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muscle-invasive urothelial cell carcinoma of the human bladder: multidirectional differentiation and ability to metastasize.
  • Few published studies have addressed the correlation between multidirectional differentiation in muscle-invasive bladder cancer and its ability to metastasize.
  • We examined cystectomy specimens from 93 bladder tumors and 1085 lymph nodes.
  • In this study, urothelial cell carcinomas (UCCs) with divergent differentiation, excluding pure divergent patterns such as squamous cell carcinoma and adenocarcinoma that tend toward a distinct biologic behavior, were subjected to histopathologic estimation.
  • [MeSH-major] Cell Differentiation. Muscles / pathology. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306328.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Izzo L, Pietrasanta D, Izzo P, Caputo M, Di Cello P, Meloni P, Bolognese A: A case of relapsing secondary bladder adenocarcinoma after right colonic cancer. Nat Clin Pract Urol; 2008 Jul;5(7):403-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
  • BACKGROUND: A 71-year-old woman was referred to a surgical oncology clinic after CT raised suspicion for a bladder neoplasm.
  • She had previously undergone right hemicolectomy and received adjuvant chemotherapy for pT3N1MX cancer of the cecum.
  • Follow-up CT raised suspicion for a possible bladder neoplasm.
  • DIAGNOSIS: Adenocarcinoma of the cecum metastatic to the bladder.
  • MANAGEMENT: The patient underwent open bladder resection with total excision of the neoplasm and was administered adjuvant chemotherapy consisting of irinotecan and cetuximab.
  • [MeSH-major] Adenocarcinoma / pathology. Cecal Neoplasms / pathology. Neoplasm Recurrence, Local / secondary. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604226.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Organoplatinum Compounds; 0 / Quinazolines; 0 / Thiophenes; 7673326042 / irinotecan; FCB9EGG971 / raltitrexed; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; Folfox protocol
  •  go-up   go-down


96. Azuma H, Yamamoto K, Inamoto T, Ibuki N, Kotake Y, Sakamoto T, Kiyama S, Ubai T, Takahara K, Segawa N, Narumi Y, Katsuoka Y: Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation. Am J Clin Oncol; 2009 Dec;32(6):592-606
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total cystectomy versus bladder preservation therapy for locally invasive bladder cancer: effect of combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
  • OBJECTIVES: We tested the usefulness of balloon-occluded arterial infusion (BOAI) of anticancer agent (cisplatin/gemcitabine), concomitant with hemodialysis, which delivers an extremely high concentration of anticancer agent to the site of a tumor without systemic adverse effects, along with concurrent radiation [Osaka-Medical College (OMC)-regimen] in patients with locally advanced bladder cancer.
  • CONCLUSION: OMC-regimen, a new strategy for patients with locally-invasive bladder cancer, can be curative not only in patients for whom cystectomy is indicated, but also in patients whose condition is not amenable to curative treatment and for whom merely palliative treatment would otherwise seem the only option.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Balloon Occlusion. Cisplatin / administration & dosage. Cystectomy. Renal Dialysis. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Choriocarcinoma / secondary. Choriocarcinoma / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infusions, Intra-Arterial. Middle Aged. Muscle Neoplasms / secondary. Muscle Neoplasms / therapy. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19593084.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


97. Taranto AJ, Lourie R, Lau WF: Ovarian vascular pedicle sign in ovarian metastasis arising from gall bladder carcinoma. Australas Radiol; 2006 Oct;50(5):504-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian vascular pedicle sign in ovarian metastasis arising from gall bladder carcinoma.
  • A case of a large mass in the pelvis confirmed to be a rare ovarian metastasis arising from a primary adenocarcinoma of the gall bladder is presented.
  • [MeSH-major] Adenocarcinoma / pathology. Gallbladder Neoplasms / pathology. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary. Ovary / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Contrast Media / administration & dosage. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Middle Aged. Positron-Emission Tomography / methods. Radiographic Image Enhancement / methods. Rare Diseases

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16981953.001).
  • [ISSN] 0004-8461
  • [Journal-full-title] Australasian radiology
  • [ISO-abbreviation] Australas Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Contrast Media; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


98. Kaufman DS, Shipley WU, Feldman AS: Bladder cancer. Lancet; 2009 Jul 18;374(9685):239-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bladder cancer.
  • Bladder cancer is a heterogeneous disease, with 70% of patients presenting with superficial tumours, which tend to recur but are generally not life threatening, and 30% presenting as muscle-invasive disease associated with a high risk of death from distant metastases.
  • The main presenting symptom of all bladder cancers is painless haematuria, and the diagnosis is established by urinary cytology and transurethral tumour resection.
  • The standard of care for muscle-invasive disease is radical cystoprostatectomy, and several types of urinary diversions are offered to patients, with quality of life as an important consideration.
  • Bladder preservation with transurethral tumour resection, radiation, and chemotherapy can in some cases be equally curative.
  • We discuss bladder preserving approaches, combination chemotherapy including new agents, targeted therapies, and advances in molecular biology.
  • [MeSH-major] Urinary Bladder Neoplasms
  • [MeSH-minor] Adenocarcinoma / epidemiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Transitional Cell / epidemiology. Chemotherapy, Adjuvant. Combined Modality Therapy. Cystectomy. Cystoscopy. Diagnosis, Differential. Hematuria / etiology. Humans. Molecular Biology. Neoadjuvant Therapy. Neoplasm Staging. Prostatectomy. Risk Factors. Sensitivity and Specificity. Survival Rate. United States / epidemiology. Urinary Diversion


99. Moussa O, Abol-Enein H, Bissada NK, Keane T, Ghoneim MA, Watson DK: Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer. J Urol; 2006 Jun;175(6):2312-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of survivin reverse transcriptase-polymerase chain reaction for noninvasive detection of bladder cancer.
  • We investigated the expression pattern of survivin in the tumors of patients with bladder cancer and assessed the diagnostic potential of RT-PCR detection of survivin mRNA in urine.
  • MATERIALS AND METHODS: RT-PCR was used to analyze mRNA expression of survivin in 161 cases of bladder cancer, including TCC in 97, SCC in 53 and adenocarcinoma in 11, and their matched nontumor tissues.
  • Urine specimens (50 ml) were collected from 84 patients in whom bladder cancer was documented by transurethral resection or biopsy, 41 with nonbladder cancer urological diseases and 42 healthy volunteers.
  • RESULTS: Survivin expression was detected in all bladder cancer tissues.
  • In contrast, survivin was not detectable in normal urothelium specimens.
  • Urinary survivin was detected in urine samples from 51 of 53 patients with TCC, 22 of 25 with SCC and 6 of 6 with adenocarcinoma.
  • Survivin mRNA was not detected in any healthy volunteers.
  • Positive results were obtained in 2 patients with renal cell carcinoma, 1 with hematuria and 1 with a contracted bladder but in none with other urological diseases.
  • CONCLUSIONS: Survivin mRNA detection in urine sediment using RT-PCR shows high sensitivity and specificity for bladder cancer.
  • [MeSH-major] Microtubule-Associated Proteins / genetics. Neoplasm Proteins / genetics. RNA, Messenger / urine. Reverse Transcriptase Polymerase Chain Reaction. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / urine

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697865.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


100. Kong CH, Singam P, Hong GE, Cheok LB, Azrif M, Tamil AM, Zainuddin ZM: Clinicopathological features of bladder tumours in a single institution in Malaysia. Asian Pac J Cancer Prev; 2010;11(1):149-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of bladder tumours in a single institution in Malaysia.
  • OBJECTIVE: To determine the clinicopathological features of bladder tumours encountered over a five year period in Universiti Kebangsaan Malaysia Medical Centre.
  • METHODS: Medical records of bladder tumour cases from 2005 till 2009 were retrospectively reviewed and tabulated.
  • The main histopathology was transitional cell carcinoma (TCC) (90.4%), followed by adenocarcinoma (6%), squamous cell carcinoma (1.2%), leiomyoma (1.2%) and myeloid sarcoma (1.2%).
  • Mean survival of patients with muscle invasive cancer was 33+/-5 months.
  • By the end of the study, 18.1% of patients had died of their cancer.
  • CONCLUSION: The incidence of bladder tumours is highest among the Chinese.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Carcinoma, Transitional Cell / secondary. Urinary Bladder Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20593947.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down






Advertisement